SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 1)
PharmaKinetics Laboratories, Inc.
- --------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, Par Value $0.001 Per Share
- --------------------------------------------------------------------------------
(Title of Class of Securities)
717131 10 6
-----------------------------
(CUSIP Number)
Leslie B. Daniels
CAI Advisors & Co.
767 Fifth Avenue, 5th Floor
New York, NY 10153
(212) 319-2525
- --------------------------------------------------------------------------------
(Name, Address and Telephone Number of Persons Authorized to Receive Notices
and Communications)
December 4, 1997
----------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box [ ].
Check the following box if a fee is being paid with this statement.| | (A fee is
not required only if the reporting person: (1) has a previous statement on file
reporting beneficial ownership of more than five percent of the class of
securities described in Item 1; and (2) has filed no amendment subsequent
thereto reporting beneficial ownership of five percent or less of such class.)
(See Rule 13d-7.)
Note: Six copies of this statement, including all exhibits, should be filed with
the Commission. See Rule 13d-1(a) for other parties to whom copies are to be
sent.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
1
<PAGE>
SCHEDULE 13D
CUSIP No. 717131 10 6
1 NAME OF REPORTING PERSON
S.S. or I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
CAI Advisors & Co.
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) X
(b) |_|
3 SEC USE ONLY
4 SOURCE OF FUNDS*
WC
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) OR 2(e) |_|
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Quebec, Canada
7 SOLE VOTING POWER
11,666,400
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON WITH
8 SHARED VOTING POWER
0
9 SOLE DISPOSITIVE POWER
11,666,400**
10 SHARED DISPOSITIVE POWER
0**
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
11,666,400**
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES* |_|
PERCENT OF CLASS REPRESENTED
13 BY AMOUNT IN ROW (11)
43.6%**
14 TYPE OF REPORTING PERSON*
PN
*SEE INSTRUCTIONS BEFORE FILLING OUT
**SEE DESCRIPTION PRESENTED UNDER THE CAPTION
"ITEM 5. INTEREST IN SECURITIES OF THE ISSUER"
2
<PAGE>
SCHEDULE 13D
CUSIP No. 717131 10 6
1 NAME OF REPORTING PERSON
S.S. or I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Aster-Cephac S.A.
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) X
(b) |_|
3 SEC USE ONLY
4 SOURCE OF FUNDS*
WC
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) or 2(e) |_|
6 CITIZENSHIP OR PLACE OF ORGANIZATION
France
7 SOLE VOTING POWER
2,916,600
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON WITH
8 SHARED VOTING POWER
0
9 SOLE DISPOSITIVE POWER
2,916,600**
10 SHARED DISPOSITIVE POWER
0**
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,916,600**
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES* |_|
13 PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (11)
10.9%**
14 TYPE OF REPORTING PERSON*
CO
*SEE INSTRUCTIONS BEFORE FILLING OUT!
**SEE DESCRIPTION PRESENTED UNDER THE CAPTION
"ITEM 5. INTEREST IN SECURITIES OF THE ISSUER"
3
<PAGE>
Item 1. Security and Issuer.
This Statement relates to 14,583,000 shares of the common stock, par
value $0.001 per share (the "Common Stock"), of PharmaKinetics Laboratories,
Inc., a Maryland corporation (the "Company"). The Company's principal executive
offices are located at 302 West Fayette Street, Baltimore, Maryland 21201.
Item 2. Identity and Background.
CAI Advisors & Co. ("CAI") and Aster-Cephac S.A. ("Aster") (together, the
"Reporting Persons") filed the Schedule 13D (the "Schedule 13D") amended by this
Amendment No. 1 to Schedule 13D on November 13, 1997. The information required
by Item 2 is included in the Schedule 13D.
Item 3. Source and Amount of Funds or Other Consideration.
The source of funds used to purchase the securities will consist of
working capital of the Reporting Persons. The aggregate amount of funds required
to purchase the Shares and Warrants (as those terms are defined in Item 4) is $5
million. The aggregate exercise price of the Warrants is $7.5 million.
Item 4. Purpose of Transaction.
The purpose of the acquisition of securities of the Company by the
Reporting Persons is for investment and to facilitate a strategic partnership
between Aster and the Company. Except as discussed in this Item 4, neither
Reporting Person currently has any plan or proposal that relates to, or would
result in, any of the actions enumerated in Item 4 of the instructions to
Schedule 13D.
On December 4, 1997, CAI, Aster, which is controlled by CAI, and the
Company entered into a Preferred Share and Warrant Purchase Agreement (such
agreement, along with the schedules thereto, the "Purchase Agreement") pursuant
to which CAI and Aster have agreed to purchase an aggregate of 833,300 shares of
the Company's Class A Convertible Preferred Stock convertible into 8,333,000
shares of Common Stock (the "Shares") and warrants to purchase an aggregate of
6,250,000 shares of Common Stock at an exercise price of $1.20 per share (the
"Warrants"). Under the Purchase Agreement, CAI is obligated to purchase 666,640
Shares and Warrants to purchase 5,000,000 shares of Common Stock, and Aster is
obligated to purchase 166,660 Shares and Warrants to purchase 1,250,000 shares
of Common Stock. The Purchase Agreement provides that CAI and Aster may assign
their rights to purchase the Shares and Warrants to certain parties with whom
they are affiliated, as well as to certain unaffiliated parties. The Reporting
Persons will file an additional amendment to the Schedule 13D to reflect the
assignment of such rights.
The Purchase Agreement provides that the Shares may be converted into
Common Stock at any time at the option of the holders and that holders will be
entitled to vote on all matters submitted to a vote of the holders of the Common
Stock and will be entitled to that number of votes equal to the number of shares
of Common Stock into which their Shares could be converted. In addition, so long
as the Conversion Shares (as hereinafter defined) constitute at least 10% of the
Total Shares Outstanding (as hereinafter defined), holders of the Shares, voting
as a separate class, will have the right to elect that number of Directors to
the Board of Directors of the Company that bears the same proportion to the
total
4
<PAGE>
number of directors on the Board as the Conversion Shares bear to the Total
Shares Outstanding. So long as the Conversion Shares constitute at least 35% of
the Total Shares Outstanding, the holders of the Shares will have the right to
elect at least 50% of the Board members. "Conversion Shares" is defined as the
number of shares of Common Stock into which the Shares could be converted plus
the number of shares of Common Stock owned by CAI, Aster, their affiliates and
certain assignees, regardless of how or when acquired. "Total Shares
Outstanding" is defined as the Company's outstanding Common Stock, plus the
number of shares of Common Stock into which the Shares could be converted.
Holders of the Shares also will have certain anti-dilution, dividend and
liquidation rights. For a complete description of the terms of the Shares, see
Schedule 1.1B to the Purchase Agreement, "Description and Designation of Class A
Convertible Preferred Stock," filed as an exhibit to this Amendment No. 1.
The Purchase Agreement provides that the Warrants will not be not
exercisable until the Company files an amendment to its charter increasing the
number of shares of Common Stock that it is authorized to issue. Thereafter, the
Warrants will be exercisable at any time for a period of three years following
the sale of the Shares and Warrants. For a complete description of the terms of
the Warrants, see Schedule 1.1C to the Purchase Agreement, "Form of Warrant,"
filed as an exhibit to this Amendment No. 1.
In addition, the Purchase Agreement provides that in the event that (i)
the Company has not by April 30, 1998 filed an amended charter increasing the
number of shares that it is authorized to issue and reserved such shares for
issuance upon exercise of the Warrants, or (ii) the Company fails to consummate
the sale of the Shares or the Warrants by December 31, 1997 (or such later date
as may be unanimously agreed by the parties to the Purchase Agreement), then the
Warrants will be cancelled and the Company will, for no additional
consideration, issue to CAI and Aster (or their assigns) warrants to purchase an
aggregate of 2,750,000 shares of Common Stock at an exercise price of $.60 per
share and otherwise having terms substantially identical to the terms of the
Warrants. The Purchase Agreement further provides that the Common Stock
underlying the Shares and the Warrants will have certain registration rights and
that the Company will enter into a technology sharing agreement with Aster. See
Schedules 5.2 and 5.3 to the Purchase Agreement, "Form of Registration Rights
Agreement" and "Form of Technology Sharing Agreement," filed as exhibits to this
Amendment No. 1.
Item 5. Interest in Securities of the Company.
In accordance with Rules 13d-3(d)(1)(i) and 13d-5(b)(1) under the
Securities Act of 1933, as amended, the Reporting Persons may be deemed to
beneficially own an aggregate of 14,583,000 shares of Common Stock, or
approximately 54.5% of the Company's outstanding Common Stock. The Reporting
Persons will have the right to acquire 8,333,000 shares of Common Stock, or
approximately 31.1% of the Company's outstanding Common Stock, based upon their
ownership of the Shares, and the right to acquire 6,250,000 shares of Common
Stock, or 23.4% of the Company's outstanding Common Stock, based upon their
ownership of the Warrants. CAI will have sole voting and dispositive power with
respect to 11,666,400 shares of Common Stock, or approximately 43.6% of the
Company's outstanding Common Stock, and Aster will have sole voting and
dispositive power with respect to the remaining 2,916,600 shares of Common
Stock, or approximately 10.9% of the Company's outstanding Common Stock.
Neither Reporting Person nor any partner, executive officer or director
of either Reporting Person, to the knowledge of either Reporting Person, had
purchased any of the Company's securities during the past sixty days.
5
<PAGE>
Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to
Securities of the Company.
None except as disclosed in Item 4.
Item 7. Material to be Filed as Exhibits.
The Purchase Agreement and certain schedules thereto are filed as
exhibits to this Amendment No. 1.
SIGNATURES
After reasonable inquiry and to the best of his knowledge and belief,
each of the undersigned certifies that the information set forth in this
Statement is true, complete and correct.
Date: December 15, 1997
CAI ADVISORS & CO.
By: /s/ LESLIE B. DANIELS
Leslie B. Daniels
Partner
ASTER-CEPHAC S.A.
By: /s/ LESLIE B. DANIELS
Leslie B. Daniels
Director
6
PREFERRED SHARE AND WARRANT PURCHASE AGREEMENT
BY AND AMONG
PHARMAKINETICS LABORATORIES, INC.,
CAI ADVISORS & CO.
AND
ASTERo CEPHAC S.A.
DECEMBER 4, 1997
- i -
<PAGE>
TABLE OF CONTENTS
Page
Section 1 PURCHASE AND SALE OF SHARES AND WARRANTS.....................1
1.1 Purchase and Sale of Shares and Warrants............1
1.2 Purchase Price......................................2
1.3 Delivery of Certificates and Payment................2
1.4 The Closing.........................................2
Section 2 REPRESENTATIONS AND WARRANTIES OF THE COMPANY................2
2.1 Organization and Standing of the Company............2
2.2 Corporate Action....................................2
2.3 Compliance with Certain Instruments.................3
2.4 Validity of Shares and Conversion Shares............3
2.5 Capitalization; Status of Capital Stock.............3
2.6 Governmental Approvals..............................4
2.7 Securities Laws.....................................4
2.8 Financial Information...............................4
2.9 Litigation..........................................4
2.10 Compliance with Law.................................4
2.11 Good Laboratory and Clinical Practices..............5
2.12 Licenses and Permits................................5
2.13 Certain Agreements of Officers and Employees........5
2.14 Transactions with Affiliates........................6
2.15 Assumptions or Guaranties of Indebtedness...........6
2.16 Investments.........................................6
2.17 Title to Assets.....................................6
2.18 Material Contracts..................................7
2.19 ERISA...............................................8
2.20 Insurance...........................................8
2.21 Registration Rights.................................8
2.22 Absence of Certain Developments.....................8
2.23 Books and Records...................................9
2.24 Disclosure..........................................9
2.25 Brokers or Finders.................................10
Section 3 REPRESENTATIONS AND WARRANTIES OF PURCHASERS................10
3.1 Investment Representations.........................10
3.2 Access to Information..............................10
3.3 Sophistication and Knowledge.......................10
3.4 Power..............................................10
Section 4 COVENANTS...................................................11
4.1 Use of Proceeds....................................11
4.2 Best Efforts Cooperation...........................11
- ii -
<PAGE>
4.3 General Covenants..................................11
4.4 Public Announcements...............................12
4.5 Confidentiality....................................12
4.6. Charter Amendments.................................12
4.7 Sales and Use Taxes................................12
4.8 Validity of Warrants...............................12
Section 5 CONDITIONS PRECEDENT TO PURCHASERS' OBLIGATIONS TO PURCHASE
THE SHARES AND THE WARRANTS.................................13
5.1 Representations and Warranties.....................13
5.2 Technology Sharing Agreement.......................13
5.3 Registration Rights Agreement......................13
5.4 Articles Supplementary.............................13
5.5 Documentation at Closing...........................13
5.6 No Actions or Proceedings..........................13
5.7 Business Combination Act Opt-out...................14
Section 6 CONDITIONS PRECEDENT TO COMPANY'S OBLIGATIONS TO SELL THE
SHARES AND THE WARRANTS.....................................14
6.1 Representations and Warranties.....................14
6.2 Technology Sharing Agreement.......................14
6.3 Documentation at Closing...........................14
6.4 No Actions or Proceedings..........................14
Section 7 CONTINGENT WARRANTS.........................................14
7.1 Contingent Warrants................................14
7.2 Opinion of Counsel.................................15
7.3 Cancellation of Warrants...........................15
Section 8 MISCELLANEOUS...............................................15
8.1 Survival of Representations and Warranties.........15
8.2 Expenses...........................................15
8.3 Notices............................................15
8.4 Modification or Waiver.............................16
8.5 Binding Effect and Assignment......................17
8.6 Governing Law......................................17
8.7 Section Headings...................................17
8.8 Further Assurances.................................17
8.9 Entire Agreement...................................17
8.10 No Third Party Beneficiaries.......................17
8.11 Counterparts.......................................17
8.12 Severability.......................................17
8.13 Termination........................................18
- iii -
<PAGE>
SCHEDULES
Schedule 1.1A Purchasers
Schedule 1.1B Description and Designation of Class A Convertible
Preferred Stock
Schedule 1.1C Form of Warrants
Schedule 2.3 Compliance with Certain Instruments
Schedule 2.5 Agreements Concerning Capital Stock
Schedule 2.9 Litigation
Schedule 2.10 Hazardous Materials
Schedule 2.12 Permits
Schedule 2.13 Agreements with Officers and Employees
Schedule 2.14 Transactions with Affiliates
Schedule 2.16 Investments
Schedule 2.17 Title to Assets
Schedule 2.18 Material Contracts
Schedule 2.19 ERISA
Schedule 2.22 Certain Developments
Schedule 5.2 Form of Technology Sharing Agreement
Schedule 5.3 Form of Registration Rights Agreement
Schedule 5.5(a) Form of Opinion of Ober, Kaler, Grimes & Shriver
- iv -
<PAGE>
PREFERRED SHARE AND WARRANT PURCHASE AGREEMENT
THIS PREFERRED SHARE AND WARRANT PURCHASE AGREEMENT is made and entered
into on this 4th day of DECEMBER 1997, by and among PHARMAKINETICS LABORATORIES,
INC. a corporation organized under the laws of the state of Maryland (the
"Company"), CAI ADVISORS & CO., a partnership organized under the laws of
Quebec, Canada ("CAI"), and ASTERo CEPHAC S.A., a company organized under the
laws of France ("Aster") (CAI and Aster, each referred to herein as a
"Purchaser" and together as the "Purchasers").
RECITALS
A. The Company desires to issue and sell to the Purchasers, and the
Purchasers desire to purchase from the Company, an aggregate of 833,300 shares
(the "Shares") of the Company's authorized but unissued shares of Class A
Convertible Preferred Stock (the "Preferred Stock"), initially convertible into
8,333,000 shares of the Company's Common Stock, par value $.001 per share (the
"Common Stock").
B. The Company desires to issue and sell to the Purchasers, and the
Purchasers desire to purchase from the Company, warrants to purchase an
aggregate of 6,250,000 shares of the Company's Common Stock at an exercise price
of $1.20 per share and with a term of three years (the "Warrants").
NOW, THEREFORE, in consideration of the representations, warranties,
conditions, and agreements hereinafter set forth, the parties hereto agree as
follows:
Section 1 PURCHASE AND SALE OF SHARES AND WARRANTS.
1.1 Purchase and Sale of Shares and Warrants. The Company agrees to
issue and sell to the Purchasers at the Closing (as hereinafter defined) and the
Purchasers agree to purchase, severally but not jointly, the Shares and the
Warrants, in the quantities set forth opposite each Purchaser's name in Schedule
1.1A. The terms of the Shares and the form of the Warrants are set forth in
Schedules 1.1B and 1.1C, respectively. The Company shall not be obligated to
issue and sell any of the Shares and the Warrants unless all of the Shares and
Warrants are purchased.
The Purchasers may assign their rights to purchase all or a portion of
the Shares and Warrants to one or more Affiliates (as defined below) or
unaffiliated third parties; provided, however, that any such assignees shall be
accredited investors as defined in Regulation D under the Securities Act of
1933, as amended (the "Securities Act"), and shall make representations to the
Company identical to the representations made by the Purchasers in Section 3;
and provided, further, that the Purchasers must obtain the written consent of
the Company prior to assigning their rights to any unaffiliated third parties,
which consent shall not be unreasonably withheld. Prior to any assignment
hereunder, the Purchasers shall identify and provide such information regarding
each assignee as the Company may reasonably request for purposes of confirming
that the assignee is an accredited investor and of complying with applicable
federal and state securities laws. For purposes of this Section 1.1,
"Affiliates" means any person that,
1
<PAGE>
directly or indirectly, through one or more intermediaries, controls, is
controlled by, or is under common control with either Purchaser, or any person
that is a partner of either Purchaser in any general or limited partnership.
1.2 Purchase Price. The aggregate purchase price for the Shares and the
Warrants shall be $5,000,000 (the "Aggregate Purchase Price") payable in cash,
of which $4,937,500 shall be allocated as the purchase price for the Shares and
$62,500 shall be allocated as the purchase price for the Warrants.
1.3 Delivery of Certificates and Payment. At the Closing (as
hereinafter defined), the Company shall issue and deliver to the Purchasers
certificates representing the Shares and Warrants, and the Purchasers shall pay
the Aggregate Purchase Price by means of a wire transfer of funds to the account
of the Company.
1.4 The Closing. The closing of the purchase and sale of the Shares and
the Warrants shall take place by telephone conference call on December 19, 1997,
or by such other means or such other date as the Purchasers and the Company may
unanimously agree (the "Closing").
Section 2 REPRESENTATIONS AND WARRANTIES OF THE COMPANY.
The Company hereby represents and warrants to each Purchaser as of the
Closing as follows:
2.1 Organization and Standing of the Company. The Company is a duly
organized and validly existing corporation in good standing under the laws of
the State of Maryland and is duly qualified and in good standing as a foreign
corporation authorized to do business in all jurisdictions wherein the character
of the property owned or leased or the nature of the activities conducted by it
makes such qualification necessary, except where the failure to be so qualified
would not have a material adverse effect on the business, operations or
financial condition of the Company. The Company has no subsidiaries with active
business operations.
2.2 Corporate Action. This Agreement, the Technology Sharing Agreement
set forth as Schedule 5.2, and the Registration Rights Agreement set forth as
Schedule 5.3 (the Technology Sharing Agreement and the Registration Rights
Agreement, along with the Warrants, being collectively herein referred to as the
"Ancillary Agreements"), and all of the transactions contemplated hereby and
thereby have been duly authorized by all required corporate action, and as of
the Closing will be duly executed and delivered, and each will constitute the
legal, valid and binding obligations of the Company, enforceable against the
Company in accordance with their respective terms. As of the date hereof, the
Company has not obtained the stockholder approval required to increase the
number of shares of Common Stock that the Company is authorized to issue in
order to reserve a sufficient number of shares of Common Stock to cover the
shares of Common Stock issuable upon exercise of the Warrants.
2
<PAGE>
2.3 Compliance with Certain Instruments. Except as listed on Schedule
2.3, the Company is in compliance in all material respects with the terms and
provisions of its Charter and By-laws, each as amended and/or restated to date,
and all mortgages, indentures, leases, agreements, judgments, decrees, orders
and other instruments by which it is bound or to which it or any of its
properties or assets are subject. Neither the execution, delivery and
performance of this Agreement or the Ancillary Agreements nor the consummation
of any transaction contemplated hereby or thereby has constituted, or with the
passage of time or giving of notice will constitute, a material default or
violation of or conflict with any term or provision of any of the foregoing
documents, instruments, laws, statutes, rules or regulations.
2.4 Validity of Shares and Conversion Shares. The Shares and the Common
Stock issuable upon conversion of the Shares and exercise of the Warrants and
the Contingent Warrants (as defined in Section 7.1) (such shares of Common
Stock, collectively, the "Conversion Shares") when issued, sold and delivered in
accordance with the terms of this Agreement will be validly issued, fully paid
and nonassessable with no personal liability attaching to the ownership thereof
and will be free and clear of all liens, charges, restrictions, claims and
encumbrances imposed by or through the Company, except as set forth in
applicable state and federal securities laws. The Company has reserved for
issuance a number of shares sufficient to enable the Purchasers to convert the
Shares and to exercise the Contingent Warrants.
2.5 Capitalization; Status of Capital Stock. As of November 30, 1997,
the authorized capital stock of the Company consisted of (i) 25,000,000 shares
of Common Stock, par value $.001 per share, and (ii) 1,500,000 shares of
Preferred Stock, without par value, of which 12,195,819 shares of Common Stock
were issued and outstanding and 1,670,425 shares reserved for issuance (not
including shares reserved for issuance in connection with the transactions
contemplated hereby) and no shares of Preferred Stock were issued or
outstanding. All the outstanding shares of capital stock of the Company have
been duly authorized, and are validly issued, fully paid and non-assessable.
With the exception of the Shares, the Warrants, the Contingent
Warrants, options to purchase 1,385,825 shares of Common Stock granted to
directors, officers and other employees of the Company, options to purchase
284,600 shares of Common Stock granted to the former Chief Executive Officer of
the Company and certain consultants of the Company, and options to purchase
1,591,200 shares of Common Stock authorized but not granted under the Company's
stock option plans, no options, warrants, subscriptions or rights of any nature
to acquire from the Company, or commitments of the Company to issue, or
securities convertible into, shares of capital stock or other securities are
authorized, issued or outstanding. None of the Company's outstanding securities
or authorized capital stock are subject to any rights of redemption, repurchase,
rights of first refusal, preemptive rights or other similar rights, whether
contractual, statutory or otherwise, for the benefit of the Company, any
stockholder, or any other person. To the Company's knowledge, and except as
contemplated by this Agreement and as set forth in Schedule 2.5, there are no
agreements, understandings, trusts or collaborative arrangements or
understandings concerning the voting or transfer of the capital stock of
3
<PAGE>
the Company. The offer and sale of all capital stock and other securities of the
Company issued prior to the Closing complied with or were exempt from all
applicable federal and state securities laws and no stockholder has a right of
rescission or damages with respect thereto.
2.6 Governmental Approvals. Except for the filing of (i) the Articles
Supplementary (as defined in Section 5.4), (ii) a charter amendment providing
for an increase in the number of authorized shares of Common Stock, (iii) the
approval of the Maryland Industrial Development Financing Authority, which
approval has been granted, and (iv) any notice that may be required under
applicable state and/or federal securities laws (which, if required, shall be
filed on or before the Closing), no authorization, consent, approval, license,
qualification, exemption of or filing or registration with any court or
governmental department, commission, board, bureau, agency or instrumentality,
domestic or foreign, is or will be necessary in connection with (i) the
execution and delivery by the Company of this Agreement or the Ancillary
Agreements, (ii) the offer, issuance, sale, execution or delivery of the Shares,
the Warrants and the Contingent Warrants, (iii) the issuance, sale, execution or
delivery of the Conversion Shares, or (iv) the performance by the Company of its
obligations under this Agreement or the Ancillary Agreements.
2.7 Securities Laws. The Company has complied with all applicable
federal and state securities laws, including the Securities Act, in connection
with the offer, issuance and sale of the Shares, the Warrants, and the
Contingent Warrants.
2.8 Financial Information. The financial statements of the Company
included in the Company's 10-K for the year ended June 30, 1997 and 10-Q for the
three months ended September 30, 1997 (the "Financial Statements") present
fairly the financial position and results of operations of the Company as of the
dates and for the periods indicated therein and have been prepared in accordance
with generally accepted accounting principles consistently applied. Except as
set forth or reserved against in the Financial Statements, the Company did not
have as of the date of the Financial Statements any material liability or
obligation of any nature, whether accrued, absolute, contingent, or otherwise
and whether due or to become due.
2.9 Litigation. Except as disclosed in Schedule 2.9, neither the
Company nor any director or officer of the Company is subject to any order,
writ, injunction or decree, of any court, commission, board or other government
agency. Except as set forth in Schedule 2.9, there are no actions, suits,
investigations or proceedings pending or threatened (nor does the Company have
any knowledge of any basis therefor) that could reasonably be expected to
result, either in any case or in the aggregate, in a material adverse change in
the business, operations, affairs or financial condition of the Company or in
any of its properties or assets, or which could reasonably be expected to call
into question the validity of this Agreement, the Ancillary Agreements, or any
action contemplated hereby or thereby.
4
<PAGE>
2.10 Compliance with Law. The Company is in compliance in all material
respects with all applicable federal, state, local and foreign laws, statutes,
rules and regulations, orders, judgments, injunctions, decrees, and similar
instruments, including those relating to the environment or occupational safety
and health. The Company has no knowledge of any pending legislation, rules or
regulations that would be likely to have a material adverse effect on the
Company's business or results of operations. The Company has not caused,
suffered or permitted any hazardous materials, oil or other petroleum products
to be generated, stored, handled, disposed or, released, spilled or discharged
at, on, from or onto the Company's premises, except as disclosed on Schedule
2.10.
2.11 Good Laboratory and Clinical Practices. The Company is in
compliance in all material respects with all "good laboratory practices" and
with all "good clinical practices," to the extent such practices are applicable
to the Company's operations, in accordance with the provisions of Title 21 of
the Code of Federal Regulations, and the Company is not the object of any notice
of insufficiency or of deficiency or of any notice of material corrective action
to be taken, from any applicable federal or state governmental agency or
regulatory body, including the U.S. Food and Drug Administration.
2.12 Licenses and Permits. The Company has all local, state, federal
and foreign licenses, permits, registrations, certificates, accreditations and
approvals (collectively, the "Permits") necessary for the Company to operate and
conduct its business as presently conducted, and there do not exist any waivers
or exemptions relating thereto. The Company is in compliance in all material
respects with, and there exist no grounds for revocation, suspension or
limitation of any of, the Permits. No notices have been received by the Company
with respect to any threatened, pending, or possible revocation, termination,
suspension or limitation of the Permits. To the Company's knowledge, each
employee of the Company has all Permits required to perform such employee's
designated functions and duties for the Company in connection with conducting
the business of the Company as presently conducted, and, to the Company's
knowledge, there exist no waivers or exemptions relating thereto. To the
Company's knowledge, there is no default under, nor does there exist any grounds
for revocation, suspension or limitation of, any such Permits. The Permits are
listed on Schedule 2.12.
2.13 Certain Agreements of Officers and Employees.
Neither the Company nor, to the Company's knowledge, any officer,
employee, agent, representative or consultant of the Company is in violation of
any term of any employment or consulting contract, confidential or proprietary
information agreement, noncompetition agreement, nonsolicitation agreement, or
any similar contract or agreement or any restrictive covenant relating to the
right of any such person to be employed or engaged by the Company, whether the
Company is party to such agreement or not. All of such agreements, and all
severance and similar agreements, to which the Company is a party are listed on
Schedule 2.13 and copies have been provided or made available to the Purchasers
or their representatives.
5
<PAGE>
No officer, consultant or employee of the Company whose termination,
either individually or in the aggregate, could have a material adverse effect on
the Company, has been terminated or has terminated his or her employment with
the Company since January 1, 1997, and no such officer, consultant or employee
of the Company has, to the Company's knowledge, the intention of terminating
such person's employment or engagement with the Company.
Schedule 2.13 sets forth each officer, employee, consultant and
contractor of the Company whose involvement, either individually or in
conjunction with others, in the design or development of property or information
proprietary to the Company, in the past two years has been, or in the future is
expected to be, material to the operations and prospects of the Company.
2.14 Transactions with Affiliates. Except as set forth in Schedule 2.13
or Schedule 2.14, there are no loans, leases, royalty agreements, guarantee
agreements or other agreements between (i) the Company or any of its customers
or suppliers and (ii) any officer, employee, consultant or director of the
Company or any person owning five percent or more of the capital stock of the
Company or, to the Company's knowledge, any member of the immediate family of
such officer, employee, consultant, director or stockholder or any corporation
or other entity controlled by such officer, employee, consultant, director or
stockholder, or a member of the immediate family of such officer, employee,
consultant, director or stockholder, and, except as set forth on Schedule 2.14,
since June 30, 1997, the Company has not repaid any principal amount of any
loans from any such person.
2.15 Assumptions or Guaranties of Indebtedness. The Company has not
assumed, guaranteed, endorsed or otherwise become directly, indirectly or
contingently liable for any indebtedness of any other person.
2.16 Investments. Except as set forth in Schedule 2.16, the Company has
not made any loans or advances to any person that are outstanding on the date of
this Agreement in excess of $50,000 in the aggregate, nor is it committed or
obligated to make any such loan or advance, nor does the Company own any equity
securities, assets comprising the business of, obligations of, or any interest
in, any person.
2.17 Title to Assets. The Company has a ninety-nine percent interest in
a limited partnership that has good and marketable title in fee to the real
property on which the Company's principal executive offices are located and the
Company enjoys peaceful and undisturbed possession of its real and personal
property under all leases under which it is operating. The limited partnership
agreement relating to such interest and all of such leases are valid and in full
force and effect, and the Company is in material compliance with such limited
partnership agreement and all such leases, which are set forth on Schedule 2.17.
The Company has good and merchantable title to all of its other assets. All of
such assets are free of any mortgages, pledges, charges, liens, security
interests or other encumbrances, except those set forth in Schedule 2.17.
6
<PAGE>
The Company has taken reasonable measures to protect and preserve the
security and confidentiality of its analytical methods, trade secrets and other
confidential information (the "Proprietary Information"). All employees and
consultants of the Company involved in the design, review, evaluation or
development of Proprietary Information have executed valid nondisclosure
agreements. None of the Proprietary Information, to the Company's knowledge, has
been used, divulged or appropriated for the benefit of any person or otherwise
to the detriment of the Company. To the Company's knowledge, no employee or
consultant of the Company has used the intellectual property, proprietary
property or information, trade secrets or other confidential information of any
other person in the course of their work for the Company, and the conduct of the
Company's business as currently operated and as proposed to be operated does not
and will not conflict with or infringe upon such property, information or trade
secrets. Except pursuant to the terms of any licenses or other agreements set
forth in Schedule 2.18, the Company has no obligation to compensate any person
to use, license or sell any such property, information or trade secrets and the
Company has not granted any person any license or other right to the Proprietary
Information, whether requiring payment of royalties or not.
2.18 Material Contracts. Except as set forth in Schedule 2.18 or
Schedules 2.13, 2.14, 2.15 or 2.16, the Company is not a party to any contract,
agreement, instrument, commitment, obligation, plan or arrangement (i) that
would be required to be disclosed in or filed as an exhibit to a Registration
Statement on Form S-1 filed with the Securities and Exchange Commission, or (ii)
with any customer or supplier providing for payments in excess of $50,000 (all
such contracts, agreements, instruments, commitments, obligations, plans and
arrangements collectively being referred to herein as "Contracts"). The Company
has made available to the Purchasers or their representatives true, correct and
complete copies of all written Contracts. Schedule 2.18 contains a list of all
written Contracts and an accurate and complete description of all Contracts that
are not in writing.
Except as set forth in Schedule 2.18, all of the Contracts are in full
force and effect, the Company and each other party to each of the Contracts has
performed all the obligations required to be performed by it to date, and there
is not under any of the Contracts any existing default, or any failure of the
Company to perform, which failure, with notice or lapse of time or both, would
constitute such a default. The Company has no present expectation or intention
of not fully performing all its obligations under each of the Contracts and has
no knowledge of any breach or anticipated breach by any other party to any of
the Contracts. Except as set forth in Schedule 2.18, none of the Contracts has
been terminated or notice of termination given with respect thereto, no notice
has been given by an party thereto of any alleged default thereunder by any
party thereto, and the Company is aware of no intention or right of any party to
any Contract to declare a default by another party to any Contract. There exists
no actual or threatened termination, cancellation, or limitation of the business
relationship of the Company with any party to any Contract. Except as set forth
in Schedule 2.18, no customer of the Company has notified the Company that it
intends to terminate or change
7
<PAGE>
its business relationship with the Company following the consummation of the
transactions contemplated hereby.
As of the dates of the Company's Financial Statements, the Company did
not have any material liability or commitment, contingent or otherwise, arising
out of any Contract and not adequately reflected in or reserved against in the
Financial Statements. Except as set forth on Schedule 2.18, none of the
Contracts contain noncompetition, exclusivity or other provisions that in any
manner restrict or in the future could restrict the Company's operations. The
Company has not recorded on its Financial Statements for any period revenue
attributable to services to be provided under any Contract that had not been
performed by the Company during such period. As of October 3, 1997, the Company
had been engaged to perform approximately $6.479 million of services for which
revenue had not been recorded on the Financial Statements, which is consistent
with the Company's experience during the last three fiscal years. The Company
has not incurred material losses in connection with any Contract that have not
been recorded on the Company's Financial Statements, other than as set forth on
Schedule 2.18.
2.19 ERISA. Except as set forth on Schedule 2.19, the Company makes no
contributions to, and has no present intention to make contributions to, any
employee pension benefit plans for its employees which are subject to the
Employee Retirement Income Security Act of 1974, as amended ("ERISA"). The
Company has never contributed to or been required to contribute to any
multi-employer plan which is subject to ERISA.
2.20 Insurance. The Company carries insurance covering its properties
and business adequate and customary for the type and scope of the properties,
assets and business, and similar to companies of comparable size and condition
similarly situated in the same industry in which the Company operates, but in
any event in amounts sufficient to prevent the Company from becoming a coinsurer
or self-insurer, with provision for reasonable deductible amounts.
2.21 Registration Rights. Except for the rights granted to the
Purchasers pursuant to the Registration Rights Agreement, no person has demand
or other rights to cause the Company to file any registration statement under
the Securities Act relating to any securities of the Company or any right to
participate in any such registration statement.
2.22 Absence of Certain Developments. Except as provided in Schedule
2.22 attached hereto, since September 30, 1997, there has been no material
adverse change in the business, assets, operations, affairs, prospects or
financial condition of the Company, and the Company has not:
(a) entered into any transaction, agreement or commitment
other than in the ordinary course of business;
(b) entered into or agreed to enter into any transaction,
agreement or commitment or suffered the occurrence of any event or events that
has interfered or is
8
<PAGE>
reasonably likely to interfere with the usual operations of the business or
that, singly or in the aggregate, has or is reasonably likely to have a material
adverse effect on the Company's business or results of operations;
(c) issued, repurchased or redeemed or agreed to issue,
purchase or redeem any stock, bonds or other corporate securities or any rights,
options or warrants with respect thereto, or paid any dividends on any shares of
the Company's capital stock;
(d) borrowed any amount or incurred or become subject to any
liabilities (absolute or contingent) except current liabilities in the ordinary
course of business comparable in nature and amount to current liabilities
incurred in the ordinary course of business during the comparable portion of its
prior fiscal year, as adjusted to reflect the current nature and volume of the
Company's business, or discharged or satisfied any lien or encumbrance or paid
any obligation or liability (absolute or contingent), other than current
liabilities paid in the ordinary course of business;
(e) mortgaged or pledged any of its assets, tangible or
intangible, or subjected them to any liens, charge or other encumbrance, except
liens for current property taxes not yet due and payable;
(f) sold, assigned or transferred any assets, except in
the ordinary course of business;
(g) made any changes in employee compensation except in the
ordinary course of business and consistent with past practices;
(h) made capital expenditures or commitments therefor that
aggregate in excess of $50,000; or
(i) incurred any material liability, obligation or commitment,
contingent or otherwise, including those arising out of any Contract, or
incurred any material losses in connection with any Contract.
2.23 Books and Records. The books of account, order books, records and
documents of the Company accurately and completely reflect all material
information relating to the business of the Company, the location and collection
of its assets, and the nature of all transactions giving rise to the obligations
or accounts receivable of the Company.
2.24 Disclosure. Neither this Agreement, the Financial Statements nor
any other agreement, document, or certificate furnished to any of the Purchasers
or their counsel by or on behalf of the Company in connection with the
transactions contemplated hereby contains any untrue statement of a material
fact or omits to state a material fact necessary in order to make the statements
made or contained herein or therein, in light of the circumstances in which
made, not misleading. This section does not relate or refer to any predictions,
projections, forecasts or estimates of future operations provided by or
9
<PAGE>
on behalf of the Company, except that all such predictions, projections,
forecasts and estimates provided by the Company to the Purchasers were prepared
in good faith. There is no fact known to the Company that has not been disclosed
herein or in writing to the Purchasers and that materially adversely affects, or
that the Company believes is reasonably likely in the future to materially
adversely affect, the business, operations, properties, assets or condition,
financial or otherwise, of the Company.
2.25 Brokers or Finders. Except for Pennsylvania Merchant Group Ltd.,
which shall receive a fee of $ 227,500 paid by the Company, no person has or
will have, as a result of the transactions contemplated by this Agreement, any
right, interest or claim against or upon the Company for any commission, fee or
other compensation as a finder or broker because of any action by the Company or
its agents.
Section 3 REPRESENTATIONS AND WARRANTIES OF PURCHASERS.
Each of the Purchasers hereby represents and warrants, severally but
not jointly, to the Company as follows:
3.1 Investment Representations. Each Purchaser intends to acquire the
Shares, the Warrants, the Contingent Warrants, and the Conversion Shares for its
own account. The Shares, the Warrants, the Contingent Warrants, and the
Conversion Shares are being acquired by it for investment and not with a view to
distribution or resale thereof. Each Purchaser understands and agrees that,
until registered under the Securities Act or transferred pursuant to Rule 144
under the Securities Act, all certificates representing the Shares, the
Warrants, any Contingent Warrants and the Conversion Shares shall bear a legend
reading substantially as follows:
The securities represented by this certificate have not been registered
under the Securities Act of 1933 or applicable state securities laws.
These securities may not be offered for sale, sold, delivered after
sale, transferred, pledged or hypothecated in the absence of an
effective registration statement covering such securities under the Act
and any applicable state securities laws, or the availability of an
exemption from registration thereunder.
3.2 Access to Information. Purchasers or their representatives have had
the opportunity to ask questions of and receive answers from management of the
Company concerning the Company's business, assets, financial condition, results
of operations, and liabilities.
3.3 Sophistication and Knowledge. Each Purchaser is an accredited
investor as defined in Regulation D under the Securities Act. Purchasers or
their representatives have the requisite knowledge and experience in financial
and business matters to render them fully capable of evaluating the merits and
risks of the purchase of the Shares and the Warrants. Each Purchaser can bear
the economic risks of its investment and can afford a complete loss of its
investment.
10
<PAGE>
3.4 Power. Each Purchaser has full power and authority to make the
foregoing representations and to enter into and to perform this Agreement and
the Ancillary Agreements in accordance with their terms. CAI is a duly organized
and validly existing partnership in good standing under the laws of Quebec,
Canada. Aster is a duly organized and validly existing corporation in good
standing under the laws of France. Each Purchaser has obtained each required
authorization, consent, approval, license, qualification, exemption of or filing
or registration with any court or governmental department, commission, board,
bureau, agency or instrumentality, domestic or foreign, necessary in connection
with (i) the execution and delivery by such Purchaser of this Agreement or the
Ancillary Agreements, (ii) its purchase of the Shares, the Warrants and the
Contingent Warrants, and (iii) its performance of its obligations under this
Agreement or the Ancillary Agreements.
Each Purchaser hereby acknowledges that the Company is relying on the
representations and warranties made by such Purchaser in this Section 3 in
connection with the Company's representation herein that it has complied with
all applicable federal and state securities laws, including the Securities Act,
in connection with the offer, issuance and sale of the Shares, the Warrants, and
the Contingent Warrants.
Section 4 COVENANTS.
4.1 Use of Proceeds. The Company shall use the proceeds from the sale
of the Shares and the Warrants to acquire instruments and software identified by
management and approved by the Board of Directors, to fund the Company's
expansion, and for working capital and general corporate purposes, including
acquisitions.
4.2 Best Efforts Cooperation. Until the Closing, the Company and
Purchasers shall use their best efforts in good faith to perform and fulfill all
conditions and obligations to be fulfilled or performed by them hereunder, to
the end that the transactions contemplated hereby will be fully and timely
consummated.
4.3 General Covenants. The Company and Purchasers agree:
(a) if any event should occur, either within or without the control of
any party, that would prevent fulfillment of the conditions to the obligations
of any party hereto to consummate the transactions contemplated by this
Agreement or the Ancillary Agreements, to use its or their reasonable efforts to
cure the same as expeditiously as possible;
(b) to cooperate fully with each other in preparing, filing,
prosecuting, and taking any other actions that may be reasonable and necessary
to obtain the consent of any governmental instrumentality, or any third party to
accomplish the transactions contemplated by this Agreement and the Ancillary
Agreements;
11
<PAGE>
(c) to deliver such other instruments, certificates, consents,
endorsements, assignments, assumptions, and other documents or instruments, in
form reasonably acceptable to the parties and their counsel, as may be
reasonably necessary to carry out and/or to comply with the terms of this
Agreement and the Ancillary Agreements and the transactions contemplated herein
and therein; and
(d) to confer on a regular basis with each other, report on material
operational matters and promptly advise each other orally and in writing of any
change or event having, or which, insofar as can reasonably be foreseen, could
have a material adverse effect on the business or operations of the Company or
which would cause or constitute a material breach of any of the representations,
warranties or covenants of any party contained herein.
4.4 Public Announcements. No public announcements shall be made by
either party without prior consent of the other with respect to this Agreement
or the transactions contemplated hereby, which consent shall not be unreasonably
withheld.
4.5 Confidentiality. CAI and their representatives shall keep
confidential all confidential information of the Company consistent with the
terms of the confidentiality agreement dated November 10, 1997 between CAI and
the Company, and Aster and their representatives shall keep confidential all
confidential information of the Company consistent with the terms of the
confidentiality agreement dated November 6, 1997 between Aster and the Company.
Any party to whom the Purchasers may assign their rights to purchase all or a
portion of the Shares and Warrants pursuant to Section 1.1 shall be required to
enter into a similar confidentiality agreement with the Company.
4.6. Charter Amendments. The Company shall use its best efforts to
obtain prior to April 30, 1998 the approval of its stockholders to amend the
Company's Charter (i) to increase the number of shares of Common Stock that the
Company is authorized to issue to a number at least sufficient to allow
Purchasers to acquire the number of shares of Common Stock to which Purchasers
would be entitled upon exercise of the Warrants, and (ii) to provide that prior
to the declaration by the Corporation of any dividend on any class of the
capital stock of the Corporation, such dividend shall have been approved by a
vote of those members of the Board of Directors elected exclusively by the
holders of the Company's Class A Convertible Preferred Stock. The Purchasers
each agree that the Shares shall be voted in favor of such Charter amendments.
Upon the approval of such a charter amendment, the Company shall deliver to each
Purchaser an opinion of counsel concerning the validity and effectiveness of the
charter amendment and otherwise substantially in the same form as the opinion
provided pursuant to Section 5.5(a).
4.7 Sales and Use Taxes. The Company shall pay any sales and use taxes
that may be imposed or due in connection with the consummation of any of the
transactions contemplated by this Agreement.
4.8 Validity of Warrants. The Company hereby covenants that it shall
not at any time assert any claim, and that it shall promptly indemnify and hold
harmless the
12
<PAGE>
Purchasers against any losses, damages or expenses (including legal expenses)
that any Purchaser may incur or suffer in connection with the assertion by any
third party of any claim, that the Warrants have not been authorized by all
required corporate action, have not been duly executed and delivered, or are not
legal, valid and binding obligations of the Company enforceable against the
Company in accordance with their terms. In the event any such claim is asserted
by any party, each Purchaser shall have the option of electing to accept, and
the Company shall issue, the Contingent Warrants pro rata based upon the number
of shares underlying Warrants held by such Purchaser. This election shall be in
addition to and not in lieu of any rights such Purchaser may have at law or in
equity as the result of a breach of this Section 4.8.
Section 5 CONDITIONS PRECEDENT TO PURCHASERS' OBLIGATIONS TO PURCHASE
THE SHARES AND THE WARRANTS.
The obligations of each Purchaser to purchase the Shares and the
Warrants are subject to the satisfaction, or waiver by the Purchasers, of the
following conditions, at or prior to the Closing:
5.1 Representations and Warranties. Each of the representations and
warranties of the Company set forth in Section 2 hereof shall be true, accurate
and correct on the date of the Closing.
5.2 Technology Sharing Agreement. Aster and the Company shall have
entered into a Technology Sharing Agreement substantially in the form of
Schedule 5.2.
5.3 Registration Rights Agreement. The Purchasers and the Company shall
have entered into a Registration Rights Agreement substantially in the form of
Schedule 5.3.
5.4 Articles Supplementary. The Company shall have duly filed with the
Maryland State Department of Assessments and Taxation ("Department") articles
supplementary including the terms of the Shares set forth in Schedule 1.1B (the
"Articles Supplementary") and the Articles Supplementary will have been accepted
by the Department and will be effective.
5.5 Documentation at Closing. The Purchasers shall have received prior
to or at the Closing each of the following documents:
(a) The opinion of Ober, Kaler, Grimes & Shriver, counsel for the
Company, in form and substance reasonably satisfactory to counsel for the
Purchasers, covering the matters set forth in Schedule 5.5(a).
(b) A certificate of the President and the Chief Financial Officer of
the Company stating that the representations and warranties of the Company
contained in Section 2 hereof and otherwise made by the Company in writing in
connection with the transactions contemplated hereby are true and correct as of
the Closing and that all conditions required to be performed prior to or at the
Closing have been performed or waived.
13
<PAGE>
(c) Any consents or waivers of governmental entities or third parties
required to be obtained at or prior to the Closing to execute and deliver this
Agreement and the Ancillary Agreements and to carry out the transactions
contemplated hereby and thereby.
5.6 No Actions or Proceedings. There shall not be any action or
proceeding by or before any court or other governmental body that shall seek to
restrain, prohibit or invalidate the transactions contemplated by this
Agreement.
5.7 Business Combination Act Opt-out. The Board of Directors of the
Company shall have adopted a resolution under Section 3-603(c)(1)(ii) of the
Maryland General Corporation Law ("MGCL") pursuant to which the Company shall
have opted out of the requirements of Section 3-602 of the MGCL with respect to
any business combination (as defined in the MGCL) involving either of the
Purchasers or their permitted assignees under Section 1.1 of this Agreement.
Section 6 CONDITIONS PRECEDENT TO COMPANY'S OBLIGATIONS TO SELL THE
SHARES AND THE WARRANTS.
The obligations of the Company to sell the Shares and the Warrants are
subject to the satisfaction, or waiver by the Company, of the following
conditions, at or prior to the Closing:
6.1 Representations and Warranties. Each of the representations and
warranties of each of the Purchasers set forth in Section 3 hereof shall be
true, accurate and correct on the date of the Closing.
6.2 Technology Sharing Agreement. Aster and the Company shall have
entered into a Technology Sharing Agreement substantially in the form of
Schedule 5.2.
6.3 Documentation at Closing. The Company shall have received prior to
or at the Closing a certificate of authorized officers of each Purchaser stating
that the representations and warranties of such Purchaser contained in Section 3
hereof and otherwise made by such Purchaser in writing in connection with the
transactions contemplated hereby are true and correct as of the Closing and that
all conditions required to be performed prior to or at the Closing have been
performed or waived.
6.4 No Actions or Proceedings. There shall not be any action or
proceeding by or before any court or other governmental body that shall seek to
restrain, prohibit, or invalidate the transactions contemplated by this
Agreement.
Section 7 CONTINGENT WARRANTS.
7.1 Contingent Warrants. In the event that (i) the Company shall not by
April 30, 1998 have filed an amended charter with the Secretary of State of
Maryland increasing the number of shares of the Company's Common Stock that it
is authorized to issue by at least 10 million shares and reserved such shares
for issuance upon exercise
14
<PAGE>
of the Warrants, or (ii) the Company shall have failed to consummate the sale of
the Shares or the Warrants by December 31, 1997 (or such later date as may be
unanimously agreed by the parties hereto) for any reason other than a breach or
default of this Agreement by the Purchasers, including a failure to pay the
Aggregate Purchase Price, or the failure by the Purchasers to satisfy a
condition set forth in Section 6 hereof, then, in either such event, the Company
shall, for no additional consideration, issue to the Purchasers warrants to
purchase an aggregate of 2,750,000 shares of the Common Stock of the Company at
an exercise price of $0.60 per share and otherwise having terms substantially
identical to the terms of the Warrants (the "Contingent Warrants"). The
Contingent Warrants shall be issued to the Purchasers pro rata based upon the
number of Shares held by each Purchaser or the number of Shares that each
Purchaser would have acquired but for the failure of the Company to consummate
the transactions contemplated by this Agreement, as the case may be.
7.2 Opinion of Counsel. Simultaneously with the issuance of Contingent
Warrants, the Company will deliver to each Purchaser an opinion of counsel in
form and substance reasonably satisfactory to such Purchaser concerning the
validity of the Contingent Warrants and otherwise substantially in the same form
as the opinion provided pursuant to Section 5.5 (a).
7.3 Cancellation of Warrants. Each Purchaser shall deliver the Warrants
to the Company for cancellation promptly upon receipt of Contingent Warrants
issued as a result of failure of the Company to amend its charter as set forth
in Section 7.1.
Section 8 MISCELLANEOUS.
8.1 Survival of Representations and Warranties. Every representation
and warranty of each of the parties set forth in this Agreement and all of the
rights and remedies of the other parties related to misrepresentations and
inaccuracies related thereto shall survive, and not be deemed waived by, the
Closing, and shall be effective regardless of any investigation that may have
been made at any time by or on behalf of any party or its directors, officers,
employees, or agents.
8.2 Expenses. The parties shall pay their respective expenses
(including the fees, disbursements, and expenses of their respective attorneys
and accountants) in connection with the negotiation and preparation of this
Agreement and the consummation of the transactions contemplated hereby.
8.3 Notices. Each party hereto shall promptly give written notice to
the other parties upon becoming aware of the occurrence of, or any impending or
threatened occurrence of, any event that would cause or constitute a breach of
any of its representations, warranties, or covenants contained in this
Agreement, and such party shall use its best efforts to prevent or promptly
remedy the same. Any notice or other communication required or which may be
given hereunder shall be in writing and shall be deemed to have been duly given
on the date delivered if delivered personally or sent by facsimile to the
persons identified below, one business day following deposit with a
15
<PAGE>
reputable overnight courier, or three business days after deposit in the U.S.
mail if mailed by certified or registered mail, return receipt requested,
addressed as follows:
If to the Company, to:
PharmaKinetics Laboratories, Inc.
302 West Fayette Street
Baltimore, MD 21201
Attention: James K. Leslie, President
Telephone: (410) 385-4500
Facsimile: (410) 385-1957
with a copy to:
Ober, Kaler, Grimes & Shriver
120 E. Baltimore Street
Baltimore, MD 21202
Attention: Melissa A. Warren, Esquire
Telephone: (410) 347-7684
Facsimile: (410) 547-0699
If to either Purchaser, to:
CAI Advisors & Co.
767 Fifth Avenue, 5th Floor
New York, NY 10153
Attention: Leslie B. Daniels
Telephone: (212) 319-2525
Facsimile: (212) 319-0232
with a copy to:
Dyer Ellis & Joseph PC
600 New Hampshire Ave., N.W.
Washington, DC 20037
Attn: Michael Joseph
Telephone: (202) 944-3000
Facsimile: (202) 944-3068
Any party may change its address to which notices or other communications are to
be sent by giving written notice of any such change in the manner provided
herein for giving notice.
8.4 Modification or Waiver. This Agreement may be amended, modified, or
superseded at any time by a written instrument executed by the Company and each
Purchaser, and any of the terms, covenants, representations, warranties, or
conditions
16
<PAGE>
hereof may be waived by the party intended to be benefited hereby. No waiver of
any nature, in any one or more instances, shall be deemed to be or construed as
a further or continued waiver of any condition or any breach of any other term,
representation, or warranty in this Agreement.
8.5 Binding Effect and Assignment. This Agreement shall be binding upon
and inure to the benefit of the parties hereto and their respective successors
and assigns.
8.6 Governing Law. This Agreement shall be governed by and
construed in accordance with the laws of the state of Maryland.
8.7 Section Headings. The Section headings contained in this Agreement
are inserted for convenience of reference only and shall not affect the meaning
or interpretation of this Agreement.
8.8 Further Assurances. Subject to the terms and conditions herein
provided, each of the parties agrees to use all reasonable efforts to take, or
cause to be taken, all action and to do, or cause to be done, all things
necessary, proper, or advisable under applicable laws and regulations to
consummate the purchase and sale of the Shares and Warrants in accordance with
the terms of this Agreement. In case at any time any further action is necessary
or desirable to carry out the purposes of this Agreement, the appropriate
officers of each party to this Agreement are hereby directed and authorized to
use their best efforts to effectuate all such action.
8.9 Entire Agreement. This Agreement and the Ancillary Agreements
embody the entire agreement and understanding between the parties hereto
relating to the subject matter hereof and supersede any prior letters of intent,
agreements, and understandings relating to the subject matter hereof, other than
confidentiality agreements executed by the parties.
8.10 No Third Party Beneficiaries. Nothing expressed or referred to in
this Agreement is intended or shall be construed to give any person other than
the parties to this Agreement or their respective successors or permitted
assigns any legal or equitable right, remedy, or claim under or in respect of
this Agreement or any provision contained herein, it being the intention of the
parties to this Agreement that this Agreement shall be for the sole and
exclusive benefit of such parties or such successors and assigns and not for the
benefit of any other person.
8.11 Counterparts. Separate copies of this Agreement may be signed by
the parties hereto, with the same effect as though all of the parties had signed
one copy of this Agreement.
8.12 Severability. If any provision of this Agreement shall be held
invalid under any applicable law, such invalidity shall not affect any other
provision of this Agreement that can be given effect without the invalid
provision and, to this end, the provisions hereof are severable.
17
<PAGE>
8.13 Termination. In the event that the Company shall have failed to
consummate the sale of the Shares and the Warrants by December 31, 1997 (or such
later date as may be unanimously agreed by the parties hereto), and the Company
has, as a result, duly issued the Contingent Warrants, then the obligations of
both parties hereunder shall terminate. In the event that the Purchasers shall
have determined not to purchase the Shares and the Warrants and shall have
provided written notice to that effect to the Company, then the obligations of
the Company hereunder shall terminate.
[Remainder of Page Intentionally Left Blank]
18
<PAGE>
IN WITNESS WHEREOF, the undersigned parties have executed this
Agreement as of the date first above written.
PHARMAKINETICS LABORATORIES, INC.
By:
James K. Leslie
President
CAI ADVISORS & CO.
By:
Leslie B. Daniels
Partner
ASTER-CEPHAC
By:
John J. Thebault
Chief Executive and President
19
<PAGE>
SCHEDULE 1.1B
DESCRIPTION AND DESIGNATION OF CLASS A CONVERTIBLE PREFERRED STOCK
1. DESIGNATION AND AMOUNT
A total of 833,300 shares of the Corporation's Preferred Stock shall be
designated the "Class A Convertible Preferred Stock."
2. VOTING RIGHTS
2.1 General Each holder of Class A Convertible Preferred Stock shall be
entitled to vote on all matters submitted to a vote of the holders of the Common
Stock of the Corporation and, with respect to each such matter, shall be
entitled to that number of votes equal to the number of whole shares of Common
Stock into which such holder's shares of Class A Convertible Preferred Stock
could be converted, pursuant to the provisions of Section 5, on the record date
for the determination of stockholders entitled to vote on such matters, or if no
such record date is established, on the date such vote is taken. Except as
otherwise provided herein or otherwise required by law, the holders of shares of
Class A Convertible Preferred Stock and the holders of shares of Common Stock
shall vote together as a single class on all matters submitted to the
stockholders of the Corporation.
2.2 Director Election Rights
(a) Definitions For purposes of this Subsection 2.2:
"Affiliate", with respect to any person, shall mean any other
person that, directly or indirectly, through one or more
intermediaries, controls, is controlled by, or is under common control
with such person, or any other person that is a partner of such person
in any general or limited partnership;
"Conversion Shares" means the sum of (A) the number of whole
shares of Common Stock into which the outstanding shares of Class A
Convertible Preferred Stock are convertible pursuant to the provisions
of Section 5, plus (B) the number of shares of Common Stock owned of
record by the Initial Holders, regardless of how or when acquired.
"Initial Holders" means CAI Advisors & Co., Astero Cephac
S.A., any Affiliate of CAI Advisors & Co. or Astero Cephac S.A., and
any holder of Class A Convertible Preferred Stock or warrants to
purchase Common Stock that obtained such preferred stock or warrants by
assignment from CAI Advisors & Co. or Astero Cephac S.A. pursuant to
the terms of that certain Preferred Stock and Warrant Purchase
Agreement dated December 3, 1997 by and among the Corporation, CAI
Advisors & Co., and Astero Cephac S.A. (the "Purchase Agreement");
1
<PAGE>
"Total Shares Outstanding" means the sum of (A) the total
number of shares of Common Stock outstanding and (B) the number of
whole shares of Common Stock into which the outstanding shares of Class
A Convertible Preferred Stock are convertible pursuant to the
provisions of Section 5.
(b) Director Election Rights of Holders So long as the Conversion
Shares constitute at least ten percent (10%) of the Total Shares Outstanding,
the holders of Class A Convertible Preferred Stock, voting as a separate class,
shall have the right to elect that number of Directors to the Board of Directors
of the Corporation (the "Board") that bears the same proportion to the total
number of directors on the Board as the Conversion Shares bear to the Total
Shares Outstanding, rounded up to the next whole number; provided, however, that
so long as the Conversion Shares constitute at least thirty-five percent (35%)
of the Total Shares Outstanding, the holders of Class A Convertible Preferred
Stock shall have the right to elect at least fifty percent (50%) of the Board
members. For purposes of this Subsection 2.2(b), the number of Conversion Shares
shall be determined on the record date for the determination of stockholders
entitled to vote on the election of directors, or if no such record date is
established, on the date such vote is taken.
3. DIVIDENDS
If the Corporation declares a dividend on its Common Stock, each holder
of shares of Class A Convertible Preferred Stock shall be entitled to
participate in such dividend as if such holder was the holder of the number of
whole shares of Common Stock into which such holder's shares of Class A
Convertible Preferred Stock could be converted, pursuant to the provisions of
Section 5, on the record date for the determination of holders of Common Stock
entitled to receive the declared dividend.
4. LIQUIDATION, DISSOLUTION, OR WINDING-UP
4.1 Preference Right Upon the liquidation, dissolution, or winding-up
of the Corporation, whether voluntary or involuntary, before any payment or
distribution shall be made to any holders of Common Stock or any other class or
series of capital stock of the Corporation designated to be junior to the Class
A Convertible Preferred Stock, the holders of Class A Convertible Preferred
Stock shall be entitled to be paid out of the assets of the Corporation
available for distribution to its stockholders, whether from capital, surplus or
earnings (the "Proceeds"), an amount per share equal to the Preference Amount
(as defined in Subsection 4.2). If the Proceeds are insufficient to pay each
holder of Class A Convertible Preferred Stock an amount per share equal to the
Preference Amount, then each such holder shall share in the Proceeds in the same
proportion that the number of shares of Class A Convertible Preferred Stock
registered in the name of such holder bears to the total number of shares of
Class A Convertible Preferred Stock outstanding.
4.2 Preference Amount The Preference Amount per share of Class A
Convertible Preferred Stock shall be Five and 92.5/100 Dollars ($5.925).
2
<PAGE>
4.3 Merger, Consolidation, etc Upon any merger, consolidation or other
corporate reorganization or combination to which the Corporation is a
non-surviving party (other than a merger into wholly-owned subsidiary of the
Corporation), or any sale of all or substantially all of the assets of the
Corporation, the holders of Class A Convertible Preferred Stock that have not
converted their shares to Common Stock pursuant to Section 5 shall be entitled
to receive the cash, securities or other property in the amount that they would
have received under Subsection 4.1 upon a liquidation.
5. CONVERSION.
5.1 Conversion Right and Conversion Rate Any holder of Class A
Convertible Preferred Stock shall have the right, at the holder's option, to
convert at any time, or from time to time, any or all of the such holder's
shares of Class A Convertible Preferred Stock into fully-paid and nonassessable
shares of the Common Stock of the Corporation, subject to the terms and
conditions of this Section 5. The number of shares of Common Stock issuable for
each share of Class A Convertible Preferred Stock upon any such conversion
(herein called the "Conversion Rate") shall be 10 shares of Common Stock for
each share of Class A Convertible Preferred Stock; provided, however, that if
the application of the then current Conversion Rate to the aggregate number of
shares of Class A Convertible Preferred Stock surrendered by a single holder in
a single transaction would result in a fraction, then the next lower whole
number of shares of Common Stock shall be issuable upon such conversion. The
Conversion Rate shall be subject to adjustment from time to time in certain
instances as provided in Section 5.3. The Corporation shall make no payment or
adjustment on account of any dividends accrued on the Common Stock issuable upon
such conversion, or on account of the rounding down to the next lower whole
number of shares issuable upon any conversion.
5.2 Manner of Conversion In order to convert shares of Class A
Convertible Preferred Stock into Common Stock, the record holder of such shares
shall surrender the certificate or certificates therefor, duly endorsed or
accompanied by duly executed stock powers, at the principal office of the
Corporation. Together with such certificates, the converting holder shall give a
written conversion notice to the Corporation of the election to convert a
specified number of shares of Class A Convertible Preferred Stock. The
converting holder shall state in its notice of conversion the name or names that
shall appear on the certificate or certificates for Common Stock issuable upon
such conversion. The Corporation shall, as soon as practicable thereafter, cause
to be issued and delivered to the converting holder, or to the converting
holder's designated transferees or nominees, if permitted by applicable law,
certificates for the number of full shares of Common Stock to which the
converting holder is entitled. If the converting holder has elected to convert
only a portion of the shares of Class A Convertible Preferred Stock represented
by the surrendered certificates, the Corporation shall issue, at its expense, a
new certificate representing the unconverted shares of Class A Convertible
Preferred Stock, registered in the name of the converting holder, or in the name
or names of the converting holder's designated transferees or nominees, if
permitted by applicable law. Shares of Class A Convertible Preferred Stock shall
be deemed to have been converted as of the close of business on the date when
the surrender of the certificates therefor and the giving of
3
<PAGE>
notice as required above has been completed. The person or persons entitled to
receive the Common Stock issuable upon conversion shall be treated for all
purposes as the record holder or holders of such Common Stock at and after such
time.
5.3. Adjustment to Conversion Rate.
(a) Generally. In order to prevent dilution of the conversion rights
granted under Section 5.1 hereof, the Conversion Rate in effect at any time
shall be subject to adjustment from time to time pursuant to this Section 5.3.
Any such adjustment shall be automatic and shall not require any further action
on the part of the Corporation (except for the preparation of an Adjustment
Certificate pursuant to Section 5.4) or of any registered owner of Class A
Convertible Preferred Stock.
(b) Sale or Issuance of Common Stock. If and whenever the Corporation
issues or sells, or in accordance with paragraph (c) of this Section 5.3 is
deemed to have issued or sold, any shares of its Common Stock for consideration
per share less than Fifty-Nine and 25/100 Cents ($0.5925) (hereafter, the
"Adjustment Trigger Price"), then immediately upon such issuance or sale (or
deemed issuance or sale) the Conversion Rate then in effect shall be increased
by multiplying such Conversion Rate by a fraction, the numerator of which shall
be the sum of (i) the number of shares of Common Stock outstanding immediately
prior to such issuance or sale (or deemed issuance or sale) plus (ii) the number
of shares of Common Stock so issued or sold (or deemed issued or sold), and the
denominator of which shall be the sum of (x) the number of shares of Common
Stock outstanding immediately prior to such issuance or sale (or deemed issuance
or sale) plus the number of shares of Common Stock that the aggregate
consideration received by the Corporation (or deemed received by the
Corporation) in connection with such issuance or sale (or deemed issuance or
sale), determined in accordance with Subsection 5.3(e) hereof, would purchase at
a price per share equal to the Adjustment Trigger Price. For purposes of this
Section 5.3, the term "Common Stock" shall include all securities of the
Corporation having characteristics substantially equivalent to those of the
Corporation's Common Stock.
(c) Deemed Sale or Issuance of Common Stock. For purposes of this
Section 5.3, the following events shall be deemed an issuance or sale of Common
Stock:
(i) Issuance of Rights, Warrants or Options. If the
Corporation in any manner grants any rights, warrants or options to
subscribe for or to purchase Common Stock (such rights, warrants or
options being herein called "Options") and the price per share for
which Common Stock is issuable upon the exercise of such Options is
less than the Adjustment Trigger Price, then the total maximum number
of shares of Common Stock issuable upon the exercise of such Options
shall be deemed to have been issued and sold by the Corporation upon
the grant of such Options for such price per share. For purposes of
this paragraph, the "price per share for which Common Stock is
issuable" will be determined by dividing (x) the total amount, if any,
received or receivable by the Corporation as consideration for the
granting of such Options, plus the minimum aggregate amount of
additional
4
<PAGE>
consideration payable to the Corporation upon the exercise of all such
Options, by (B) the total maximum number of shares of Common Stock
issuable upon the exercise of all such Options. No further adjustment
of the Conversion Rate shall be made when shares of Common Stock are
actually issued upon the exercise of such Options.
(ii) Issuance of Convertible Securities. If the Corporation in
any manner issues or sells any securities convertible into or
exchangeable for Common Stock (such convertible or exchangeable
securities being herein called "Convertible Securities") and the price
per share for which Common Stock is issuable upon such conversion or
exchange is less than the Adjustment Trigger Price, then the total
maximum number of shares of Common Stock issuable upon the conversion
or exchange of such Convertible Securities shall be deemed to have been
issued and sold by the Corporation for such price per share upon the
issuance or sale of such Convertible Securities. For purposes of this
paragraph, the "price per share for which Common Stock is issuable"
shall be determined by dividing (x) the total amount received or
receivable by the Corporation as consideration for the issuance or sale
of such Convertible Securities, plus the minimum aggregate amount of
additional consideration, if any, payable to the Corporation upon the
conversion or exchange thereof, by (y) the total maximum number of
shares of Common Stock issuable upon the conversion or exchange of all
such Convertible Securities. No further adjustment of the Conversion
Rate shall be made when shares of Common Stock are actually issued upon
the conversion or exchange of such Convertible Securities.
(iii) Treatment of Expired Options and Unexercised Convertible
Securities. Upon the expiration of any Option or the termination of any
right to convert or exchange any Convertible Securities without
exercise of the underlying option or right, provided such Options or
Convertible Securities are not reissued by the Corporation, the
Conversion Rate then in effect hereunder will be adjusted to the
Conversion Rate that would have been in effect at the time of such
expiration or termination had such Option or Convertible Security, to
the extent outstanding immediately prior to such expiration or
termination, never been issued.
(iv) Integrated Transactions. In case any Option is issued in
connection with the issuance or sale of other securities of the
Corporation together comprising one integrated transaction in which no
specific consideration is allocated to such Option by the parties
thereto, the Option shall be deemed to have been issued for a
consideration of One Cent ($0.01).
(d) Certain Events Excepted. Notwithstanding the other provisions of
this Section 5.3, the following events shall not trigger an adjustment to the
Conversion Rate:
(i) the issuance or sale (or deemed issuance or sale) of
Common Stock reserved for issuance in connection with the Conversion of
Class A Convertible Preferred Stock;
5
<PAGE>
(ii) the issuance or sale (or deemed issuance or sale) of
Common Stock reserved for issuance upon the exercise of warrants
purchased under the Purchase Agreement; and
(iii) the grant of Options, or the issuance or sale (or deemed
issuance or sale) of Common Stock, to officers, employees, directors,
consultants or advisors of the Corporation pursuant to any stock option
plan or restricted stock purchase plan adopted by the Corporation.
(e) Calculation of Consideration Received. If any Common Stock, Option
or Convertible Security is issued or sold, or deemed to have been issued or
sold, for cash, the consideration received therefor shall be deemed to be the
net amount of cash received by the Corporation therefor. In case any Common
Stock, Option or Convertible Security is issued or sold for a consideration
other than cash, the amount of the consideration other than cash received by the
Corporation shall be the fair market value of such consideration. If any Common
Stock, Option or Convertible Security is issued in connection with any merger in
which the Corporation is the surviving corporation, the amount of consideration
therefor shall be deemed to be the fair market value of such portion of the net
assets and business of the non-surviving corporation as is attributable to such
Common Stock, Option or Convertible Security, as the case may be. The fair
market value of any consideration other than cash and securities shall be
determined by the Board of Directors of the Corporation.
(f) Dividend in Common Stock If the Corporation pays a dividend in
shares of its Common Stock, the Conversion Rate shall be increased by
multiplying the Conversion Rate then in effect by a fraction, the numerator of
which shall be the sum of (A) the number of shares of Common Stock outstanding
at the opening of business on the date fixed for such dividend plus (B) the
total number of shares constituting such dividend, and the denominator of which
shall be the number of shares of Common Stock outstanding at the opening of
business on the date fixed for such dividend.
(g) Subdivision or Combination of Common Stock. If the Corporation at
any time subdivides (by any stock split, stock dividend, recapitalization or
otherwise) the outstanding shares of Common Stock into a greater number of
shares, the Conversion Rate and the Adjustment Trigger Price in effect
immediately prior to such subdivision will be, respectively, proportionately
increased and decreased. If the Corporation at any time combines (by reverse
stock split or otherwise) the outstanding shares of Common Stock into a smaller
number of shares, the Conversion Rate and the Adjustment Trigger Price in effect
immediately prior to such combination will be, respectively, proportionately
decreased and increased.
(h) Waiver of Automatic Adjustment. An automatic adjustment to the
Conversion Rate or the Adjustment Trigger Price pursuant to this Section 5.3 may
not be waived except by written notice to the Corporation executed by the
registered owners of 100 percent of then outstanding shares of Class A
Convertible Preferred Stock.
6
<PAGE>
5.4 Adjustment Certificate The Treasurer or Chief Financial Officer of
the Corporation shall compute all required adjustments to the Conversion Rate or
the Adjustment Trigger Price under this Section 5 and shall prepare a
certificate setting forth the adjusted Conversion Rate or Adjustment Trigger
Price and showing in detail the facts upon which the adjustment was based (the
"Adjustment Certificate"). The Treasurer or Chief Financial Officer shall
promptly file the Adjustment Certificate with the Transfer Agent, if any, for
the Class A Convertible Preferred Stock and shall promptly mail a copy of the
Adjustment Certificate to each record holder of Class A Convertible Preferred
Stock.
5.5 Notice of Certain Events In case:
(i) the Corporation shall declare a dividend payable in
Common Stock;
(ii) of any capital reorganization of the Corporation,
reclassification of the capital stock of the Corporation, consolidation
or merger of the Corporation with or into another corporation, or
conveyance of all or substantially all of the assets of the Corporation
to another corporation; or
(iii) of the voluntary or involuntary dissolution, liquidation
or winding-up of the Corporation;
then, and in any such case, the Corporation shall cause to be mailed to the
Transfer Agent, if any, for the Class A Convertible Preferred Stock and to the
record holders of the outstanding shares of Class A Convertible Preferred Stock,
at least twenty days prior to the record date for any such event, a notice
disclosing the event to occur and the record date for determination of the
stockholders entitled to participate in such event.
5.6 Common Stock Reserve The Corporation shall at all times reserve and
keep available, out of its authorized but unissued Common Stock, solely for the
purpose of effecting the conversion of the shares of Class A Convertible
Preferred Stock, the full number of shares of Common Stock issuable upon the
conversion of all shares of Class A Convertible Preferred Stock from time to
time outstanding.
5.7 Taxes The Corporation shall pay any and all issue taxes that may be
payable in respect of the issuance or delivery of shares of Common Stock upon
conversion of shares of Class A Convertible Preferred Stock.
6. RESTRICTIONS AND LIMITATIONS ON CORPORATE ACTION
The approval by vote of the holders of at least a majority of the
outstanding shares of Class A Convertible Preferred Stock, voting as a single
class, each share of Class A Convertible Preferred Stock to be entitled to one
vote in each instance, shall be required for any action by the Corporation or
any amendment to the corporate charter if such corporate action or amendment
would (i) change or limit any of the rights, preferences, or privileges of the
Class A Convertible Preferred Stock, or (ii) authorize, create, or issue, or
obligate the Corporation to authorize, create, or issue, additional shares of
Class A
7
<PAGE>
Convertible Preferred Stock or shares of any other class or series of stock
having rights, preferences, or privileges senior to or on a parity with those of
the Class A Convertible Preferred Stock.
7. NO IMPAIRMENT
The Corporation will not, by amendment of its corporate charter or
through any reorganization, transfer of capital stock or assets, consolidation,
merger, dissolution, issue or sale of securities, or through any other voluntary
action, avoid or seek to avoid the observance or performance of any of the terms
of the Class A Convertible Preferred Stock, but will at all times in good faith
assist in the carrying out of all such terms.
8. NO REISSUANCE OF CLASS A CONVERTIBLE PREFERRED STOCK; TERMINATION
No share or shares of Class A Convertible Preferred Stock acquired by
the Corporation by reason of conversion or otherwise shall be reissued, and all
such shares shall be canceled, retired and eliminated from the shares which the
Corporation is authorized to issue. Upon the cancellation of all outstanding
shares of the Class A Convertible Preferred Stock, these charter provisions
regarding the Description and Designation of Class A Convertible Preferred Stock
shall terminate and have no further force and effect.
8
<PAGE>
SCHEDULE 1.1(C)
FORM OF WARRANT
THE WARRANTS AND COMMON STOCK ISSUABLE UPON THEIR EXERCISE HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933 OR APPLICABLE STATE SECURITIES LAWS.
THESE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, DELIVERED AFTER SALE,
TRANSFERRED, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION
STATEMENT COVERING SUCH SECURITIES UNDER THE ACT AND ANY SUCH LAWS OR THE
AVAILABILITY OF AN EXEMPTION FROM REGISTRATION THEREUNDER.
PHARMAKINETICS LABORATORIES, INC.
COMMON STOCK PURCHASE WARRANT
1. Issuance. For good and valuable consideration the receipt of which
is hereby acknowledged, PHARMAKINETICS LABORATORIES, INC., a Maryland
corporation (the "Company"), hereby grants to (the "Holder") the right to
purchase at any time and from time to time until 5:00 P.M. Eastern Standard Time
on December , 2000 (the "Expiration Date"), fully paid and nonassessable shares
of the Company's Common Stock, par value $0.001 per share (the "Common Stock")
at an exercise price of $1.20 per share (the "Exercise Price"), subject to the
limitation set forth in Section 2(b) and to adjustment as set forth in Section
6.
2. Exercise. (a) The warrants represented by this Certificate (the
"Warrants") are exercisable, in whole or in part, by surrendering to the Company
(i) this Certificate, (ii) the attached form of notice of exercise of the
Warrants, and (iii) unless the Holder elects "cashless exercise" of the
Warrants, cash or a certified or official bank check in the amount of the
aggregate Exercise Price. In the event the Holder elects cashless exercise of
the Warrants, the Holder shall be entitled to receive a number of shares of
Common Stock equal in Market Value to the difference between the Market Value of
the shares of Common Stock issuable upon exercise of the Warrants and the
aggregate cash Exercise Price thereof. For purposes of this Section 2, "Market
Value" shall be an amount equal to the average of the closing sales price of a
share of Common Stock for the ten (10) days immediately preceding the Company's
receipt of the form of notice of exercise duly executed, via delivery or
facsimile, multiplied by the number of shares of Common Stock to be issued upon
exercise. Upon surrender of this Certificate and the notice of exercise form
duly executed, together with payment of the Exercise Price for the shares of
Common Stock purchased, the Company promptly shall send or cause to be sent to
the Holder a certificate or certificates representing the shares of Common Stock
purchased. Upon the exercise of less than all of the Warrants evidenced by this
Certificate, the Company promptly shall send to the Holder a new Warrant
Certificate representing the unexercised portion of the Warrants.
(b) The Warrants shall not be exercisable until the Company shall have
filed with the State of Maryland Department of Assessments and Taxation (the
"Department") an amendment of the Company's charter increasing the number of
shares Common Stock
1
<PAGE>
that it is authorized to issue to at least 35 million shares. If the Company has
not filed such amendment with the Department by April 30, 1998 (or such later
date as may be unanimously agreed by the parties to that certain Preferred Share
and Warrant Purchase Agreement dated as of December 4, 1997 by and among the
Company, CAI Advisors & Co. and Astero Cephac S.A. (the "Agreement")), the
Warrants and the Holder's rights hereunder shall terminate.
3. Reservation of Shares. The Company agrees that at all times during
the period of exercise of these Warrants there shall be reserved for issuance at
least that number of shares of Common Stock required to be issued upon exercise
of the Warrants (the "Warrant Shares").
4. Mutilation or Loss of Warrant. Upon receipt by the Company of
evidence satisfactory to it of the loss, theft, destruction or mutilation of
this Warrant Certificate, and, in the case of loss, theft or destruction,
receipt of reasonably satisfactory indemnification, and, in the case of
mutilation, upon surrender and cancellation of this Certificate, the Company
will execute and deliver a new Warrant Certificate of like tenor and date and
any such lost, stolen, destroyed or mutilated Warrant Certificate shall
thereupon become void.
5. Rights of the Holder. The Holder shall not, by virtue hereof, be
entitled to any rights of a stockholder in the Company, either at law or equity,
and the rights of the Holder are limited to those expressed in this Warrant
Certificate and are not enforceable against the Company except to the extent set
forth herein.
6. Protection Against Dilution. The number of shares of Common Stock
that the Holder is entitled to purchase upon exercise of the Warrants and the
Exercise Price shall be subject to adjustment from time to time as follows:
(a) Adjustment for Subdivision. If the Company at any time
subdivides (by any stock split, stock dividend, recapitalization or otherwise)
the outstanding shares of Common Stock into a greater number of shares, the
number of shares that the Holder is entitled to purchase upon exercise of the
Warrants shall be proportionately increased and the Exercise Price in effect
immediately prior to such subdivision shall be proportionately reduced, and if
the Company at any time combines (by reverse stock split or otherwise) the
outstanding shares of Common Stock into a smaller number of shares, the number
of shares that the Holder is entitled to purchase upon exercise of the Warrants
shall be proportionately decreased and the Exercise Price in effect immediately
prior to such combination and the number of shares of Common Stock to be
received by the Holder pursuant to the Warrants shall be proportionately
increased.
(b) Adjustment for Reorganization. Any capital reorganization,
reclassification, consolidation, merger or sale of all or substantially all of
the Company's assets with or into another person or entity that is effected in
such a manner that holders of Common Stock are entitled to receive (either
directly or upon subsequent liquidation) stock, securities or assets with
respect to or in exchange for Common Stock shall be
2
<PAGE>
referred to herein as an "Organic Change." Prior to the consummation of any
Organic Change, the Company shall make appropriate lawful provisions to ensure
that the Holder shall thereafter have the right to acquire and receive upon
exercise of the Warrants during the period specified herein and upon payment of
the Exercise Price then in effect such shares of stock, securities or assets as
the Holder would have received in connection with such Organic Change if the
Holder had exercised the Warrants immediately prior to such Organic Change.
7. Transfer Complies with Securities Act. The Warrants have not been
registered under the Securities Act of 1933, as amended, (the "Securities Act")
and have been issued to the Holder for investment and not with a view to the
distribution of either the Warrants or the Warrant Shares. Neither the Warrants
nor any of the Warrant Shares may be sold, transferred, pledged or hypothecated
in the absence of an effective registration statement under the Securities Act
relating to such security or an opinion of counsel reasonably satisfactory to
the Company that registration is not required under the Securities Act. Each
Certificate for the Warrants and the Warrant Shares shall contain a legend on
the face thereof, in form and substance satisfactory to counsel for the Company,
setting forth the restrictions on transfer contained in this Section 7.
8. Notices. Any notice or other communication required or permitted
hereunder shall be in writing and shall be delivered personally, telegraphed,
telexed, sent by facsimile transmission or sent by certified, registered or
express mail, postage pre-paid. Any such notice shall be deemed given when so
delivered personally, telegraphed, telexed or sent by facsimile transmission,
or, if mailed, two days after the date of deposit in the United States mails, as
follows:
If to the Company, to:
PharmaKinetics Laboratories, Inc.
302 West Fayette Street
Baltimore, MD 21201
Attention: James K. Leslie, President
Telephone: (410) 385-4500
Facsimile: (410) 385-1957
with a copy to:
Ober, Kaler, Grimes & Shriver
120 E. Baltimore Street
Baltimore, MD 21202
Attention: Melissa A. Warren, Esquire
Telephone: (410) 347-7684
Facsimile: (410) 547-0699
3
<PAGE>
If to Holder, to:
[Astero Cephac S.A. ]
[c/o] CAI Advisors & Co.
767 Fifth Avenue, 5th Floor
New York, NY 10153
Attention: Leslie B. Daniels
Telephone: (212) 319-2525
Facsimile: (212) 319-0232
with a copy to:
Dyer Ellis & Joseph PC
600 New Hampshire Ave., N.W.
Washington, DC 20037
Attn: Michael Joseph
Telephone: (202) 944-3000
Facsimile: (202) 944-3068
Any party may designate another address or person for receipt of notices
hereunder by notice given to the other parties in accordance with this Section
8.
9. Transfer. The Holder shall not transfer the Warrants without the
prior written consent of the Company except to parties to whom the rights to
purchase the Shares (as that term is defined in the Agreement) or the Warrants
have been assigned pursuant to Section 1.1 of the Agreement.
10 Governing Law. This Warrant Certificate shall be governed by and
construed in accordance with the laws of the state of Maryland.
11. Supplements and Amendments. This Warrant Certificate may be
amended or supplemented only by an instrument in writing signed by the parties
hereto.
12. Counterparts. This Warrant Certificate may be executed in any
number of counterparts and each such counterpart shall for all purposes be
deemed to be an original, and all such counterparts shall together constitute
one and the same instrument.
4
<PAGE>
IN WITNESS WHEREOF, the parties have executed this Warrant
certificate as of the day of December 1997.
PHARMAKINETICS LABORATORIES, INC.
By:
James K. Leslie
President
[HOLDER]
By:
Name:
Title:
5
<PAGE>
NOTICE OF EXERCISE OF WARRANTS
The undersigned hereby irrevocably elects to exercise the right,
represented by the attached Common Stock Purchase Warrant Certificate dated as
of (the "Certificate") to purchase shares of the Common Stock, par value $0.001
per share, of PharmaKinetics Laboratories, Inc. and either (i) tenders herewith
payment in accordance with said Certificate or (ii) elects "cashless exercise"
in accordance with the Certificate, as indicated below.
The undersigned hereby confirms and acknowledges that the undersigned
will not offer, sell or otherwise dispose of any shares of Common Stock received
upon exercise of the Warrants except pursuant to an effective registration
statement under the Securities Act of 1933, as amended, and applicable state
securities laws or pursuant to an exemption form registration in accordance with
such Act and laws.
Please issue in the name of the undersigned a new Common Stock Purchase
Warrant Certificate representing the unexercised portion of the Warrants
represent by the attached Certificate.
Please issue the stock certificate(s) in the names and denominations
and deliver them to the addresses set forth below:
Dated:______________________
By:_________________________
|_| CASH: $ _______________________
|_| CASHLESS EXERCISE
<PAGE>
SCHEDULE 5.3
FORM OF REGISTRATION RIGHTS AGREEMENT
THIS REGISTRATION RIGHTS AGREEMENT is made and entered into on this day
of DECEMBER 1997, by and among PHARMAKINETICS LABORATORIES, INC. a corporation
organized under the laws of the state of Maryland (the "Company"), CAI ADVISORS
& CO., a partnership organized under the laws of Quebec, Canada ("CAI"), and
ASTERo CEPHAC S.A., a company organized under the laws of France ("Aster") (CAI,
Aster and any successors and assigns permitted pursuant to Section 7(c) each
being referred to herein as a "Stockholder" and collectively as the
"Stockholders").
RECITALS
A. The Company, CAI and Aster are parties to a Preferred Stock and
Warrant Purchase Agreement dated December 4, 1997 (the "Purchase Agreement")
pursuant to which CAI and Aster or their assigns will purchase an aggregate of
833,300 shares of PharmaKinetics Class A Convertible Preferred Stock convertible
into 8,333,000 shares of PharmaKinetics Common Stock, par value $.001 per share
(the "Shares") and warrants to purchase an aggregate of 6,250,000 shares of
PharmaKinetics Common Stock with an exercise price of $1.20 per share (the
"Warrants").
B. The execution of this Agreement is a condition precedent to the
obligations of CAI and Aster under the Purchase Agreement to consummate the
purchase of the Shares and the Warrants.
NOW, THEREFORE, in consideration of the Purchase Agreement and the
conditions and agreements hereinafter set forth, the parties agree as follows:
Section 1. DEMAND REGISTRATION RIGHTS
(a) Request for Registration. A Stockholder or Stockholders holding
Shares, Warrants, Contingent Warrants and/or Conversion Shares that in the
aggregate represent at least 50% of the Underlying Shares then held by the
Stockholders shall have the right on two occasions to request the Company, in
writing, to effect the registration of Conversion Shares with the Securities and
Exchange Commission (the "Commission") pursuant to the Securities Act of 1933,
as amended (the "Securities Act"); provided, however, that the Stockholders may
not demand registration on more than one occasion within the twelve-month period
following the Closing. Such written request shall specify the number of
Conversion Shares to be registered and the intended method of disposition of
such Conversion Shares. For purposes of this Section 1(a), "Underlying Shares"
shall include the shares of Common Stock underlying the Shares, the Warrants,
and the Contingent Warrants, as well as any Conversion Shares.
(b) Notice to Stockholders. Upon receipt of the written request
referred to in Section 1(a), the Company shall (i) within five days give notice
of the requested registration to all other Stockholders (including information
regarding the intended method of disposition of the Conversion Shares), who may
then elect to participate in such
1
<PAGE>
registration by giving the Company notice of such election within 20 days after
notice of the requested registration is received, and (ii) use its best efforts
to effect the registration on Form S-3 (or other appropriate form) of the
Conversion Shares for which the Stockholders have requested registration.
(c) Limitation on Rights. Notwithstanding any other provisions of this
Section 1, the Company shall not be obligated to register Conversion Shares if
(i) all of the Conversion Shares for which the Stockholders have requested
registration are eligible for sale pursuant to Rule 144 under the Securities Act
without regard to the volume limitations set forth in Rule 144 and Company
causes its agents promptly to transfer shares eligible for sale under Rule 144,
or (ii) the aggregate proceeds of the offering of the Conversion Shares so
registered (after deduction of underwriting discounts and selling commissions)
will not exceed $150,000.
Notwithstanding any other provisions of this Section 1, the
Stockholders shall not demand registration of the Conversion Shares in the event
that the Board of Directors of the Company has approved the filing of a
registration statement covering securities issued for the Company's account in a
firm commitment underwritten public offering and has notified the Stockholders
of such proposed filing, beginning 60 days prior to the intended date of such
filing as set forth on such notice and ending upon the earlier of (i) such
intended filing date, if such registration statement has not then been filed, or
(ii) 60 days following the effective date of such registration statement;
provided that the Company is actively employing in good faith all reasonable
efforts to cause such registration statement to become effective; and provided,
further, that the Stockholders may include or could have included the Conversion
Shares in such registration statement pursuant to Section 2.
Notwithstanding any other provisions of this Section 1, if, at the time
of any request to register Conversion Shares pursuant to this Section 1, the
Company is engaged or intends to engage in any acquisition, disposition, merger,
business combination, corporate reorganization, or other transaction or
development that has not been publicly disclosed and which, in the good faith
determination of the Company's Board of Directors, would be adversely affected
by the requested registration, then the Board of Directors may direct that such
request be delayed until such transaction or development is publicly disclosed
or has been abandoned, but in any event for a period not to exceed 60 days. In
such event, the Stockholders shall be deemed to have withdrawn their request for
registration and such request shall not be counted as a demand registration to
which such Stockholders are entitled pursuant to this Section 1.
The Company shall not be entitled to invoke its rights set forth in
this Section 1(c) more than one time in any 12-month period.
(d) Underwriting. In the event the Stockholders requesting registration
intend to distribute the Conversion Shares by means of an underwriting, the
right of any
2
<PAGE>
Stockholders to be included in such registration shall be conditioned upon such
Stockholders' agreement to pay their pro rata share of the underwriting
discounts and commissions.
The Company and the Stockholders holding the Conversion Shares to be
registered shall enter into an underwriting agreement with an underwriter
selected by the Stockholders and approved by the Board of Directors of the
Company (which approval shall not be unreasonably withheld) requesting the
registration under Section 1(a). Such agreement shall contain the
representations, warranties, and covenants and other terms as are customarily
contained in agreements of that type and shall be reasonably satisfactory in
form and substance to Company and the Stockholders holding the Conversion Shares
being registered.
Notwithstanding any other provisions of this Section 1, if such
underwriter advises the Company in writing that marketing factors require a
reduction in the number of Conversion Shares to be underwritten, then the
Company shall so advise the Stockholders holding the Conversion Shares to be
registered, and the number of Conversion Shares that are included in the
registration statement shall be reduced in accordance with such requirements pro
rata among Stockholders in accordance with the number of Conversion Shares being
registered. The written notification from such underwriter to the Company shall
include a reasonable basis for such underwriter's advice.
The Company shall not include or permit the inclusion of any securities
other than the Conversion Shares in any registration statement filed pursuant to
the provisions of this Section 1 without the prior written consent of the
holders of the Conversion Shares being registered.
Section 2. PIGGYBACK REGISTRATION RIGHTS
(a) Request for Registration. If the Company proposes to register any
of its securities under the Securities Act on Form S-1, S-2 or S-3 (or any
equivalent general registration form then in effect not relating to employee
benefit plans or transactions covered by Rule 145 under the Securities Act), the
Company shall: (i) promptly give written notice of such registration to each
Stockholder, and (ii) include in such registration the Conversion Shares
specified in any written requests received from such Stockholders within 20 days
following delivery of such notice.
(b) Limitation on Rights. Notwithstanding any other provisions of this
Section 2, the Company shall have the right at any time after it has given
notice of the filing of a registration pursuant to this Section 2 to elect not
to proceed with such registration.
Notwithstanding any other provisions of this Section 2, the Company
shall not be obligated to register Conversion Shares if such Conversion Shares
are eligible for sale pursuant to Rule 144 under the Securities Act without
regard to the volume limitations set forth in Rule 144.
3
<PAGE>
Notwithstanding any other provisions of this Section 2, if the
Company's managing underwriter advises the Company in writing that the number of
Conversion Shares requested to be included in the registration statement exceeds
the number of such Conversion Shares that can be sold in an orderly manner in
the offering or that the inclusion of such Conversion Shares would adversely
affect the offering, then the Company shall be required to include only that
number of Conversion Shares that would not exceed such number or have such
adverse effect. The written notification from such underwriter to the Company
shall include a reasonable basis for such underwriter's advice. In the event
that it is necessary to reduce the number of Conversion Shares to be included in
the registration statement, such reduction shall be made pro rata among
Stockholders in accordance with the number of Conversion Shares being
registered. Notwithstanding the other provisions of this Section 2, no reduction
in the number of Conversion Shares being registered shall be effected unless the
Conversion Shares represent the only securities held by any selling shareholders
covered by the registration statement. To the extent that following the date of
this Agreement the Company grants rights to any person or entity to participate
in any registration statement, the agreement setting forth such rights shall
provide that such rights shall in all respects be subordinate to the rights set
forth in this Agreement.
Section 3. INFORMATION PROVIDED BY STOCKHOLDERS
Any Stockholder whose Conversion Shares are included in any
registration statement hereunder shall furnish to the Company such information
regarding such Stockholder and the intended method of distribution of the
Conversion Shares as the Company may request in writing.
Section 4. EXPENSES OF REGISTRATION
All fees and expenses in connection with any registration hereunder,
including registration fees, printing expenses, blue sky fees and expenses and
the Company's legal and accounting fees and expenses shall be borne by the
Company. Underwriting discounts and selling commissions and legal counsel fees
shall be borne by the Stockholders pro rata in accordance with the number of
Conversion Shares being registered.
Section 5. REGISTRATION PROCEDURES
Whenever the Company shall be required to register any Conversion
Shares hereunder, the Company shall, as expeditiously as possible:
(a) Filings. Prepare and file with the Commission, and use its best
efforts to cause to be declared and remain continuously effective for a period
of time not exceeding 120 days, the registration statement and any amendments
and supplements thereto and the prospectus used in connection therewith as may
be necessary to keep the registration statement current and to comply with the
provisions of the Securities Act with respect to the disposition of Conversion
Shares covered by the registration statement.
4
<PAGE>
Notwithstanding the other provisions of this Section 5(a), in the event the
registration statement is filed on Form S-3 (or a successor form that permits
incorporation by reference), the Company shall use its best efforts to cause
such registration statement to remain continuously effective for a period of
time not exceeding two years; provided, however, that the rules under the
Securities Act permitting the incorporation by reference of information
contained in periodic reports filed under the Securities Exchange Act of 1934,
as amended, are not repealed or amended in a manner so as to materially limit
the amount of such information that may be so incorporated by reference and the
rules under the Securities Act permitting offerings on a continued or delayed
basis are not repealed.
(b) Copies of Documents. Furnish to each Stockholder participating in
the offering and each underwriter, if any, copies of the registration statement
and each amendment and supplement thereto and copies of the prospectus included
therein (including each summary, preliminary, final, amended or supplemented
prospectus) in conformity with the requirements of the Securities Act and copies
of such other documents as each such Stockholder and underwriters, if any, shall
reasonably require in order to facilitate the disposition of the Conversion
Shares, but only while the Company is required under the provisions hereof to
keep the registration statement current.
(c) Blue Sky Compliance. Use its best efforts to register or qualify
the Conversion Shares covered by the registration statement under such other
securities or blue sky laws of such jurisdictions in the United States as the
Company or the managing underwriter, if any, determine is reasonably necessary
to enable each participating Stockholder to consummate the disposition of the
Conversion Shares owned by it in compliance with the laws of such jurisdiction;
provided, however, that the Company shall not be required to subject itself to
any suit (other than suits arising in connection with the sale of the Conversion
Shares) in any jurisdiction where it has not theretofore done so.
(d) Experts. Furnish to each underwriter participating in the offering
(i) an opinion of counsel to the Company dated the effective date of such
registration statement and the date of the closing under the underwriting
agreement, and (ii) a "cold comfort" letter dated the effective date of such
registration statement and the date of the closing under the underwriting
agreement signed by the independent public accountants who have issued a report
on the Company's financial statements included in such registration statement,
in each case covering the matters agreed upon by the parties to the underwriting
agreement.
(e) Material Information. Immediately (i) notify each Stockholder
participating in the offering and the managing underwriter, if any, of any event
that results in the prospectus included in the registration statement, as then
in effect, including any untrue statement of a material fact or omitting to
state any material fact required to be stated therein or necessary to make the
statements therein, in the light of the circumstances then existing, not
misleading, and (ii) amend or supplant such prospectus as may be necessary so
that such prospectus shall not include any untrue statement of a material fact
or omit to state any material fact required to be stated therein or necessary to
make the
5
<PAGE>
statements therein, in light of the circumstances then existing, not misleading,
and so that such prospectus will comply with applicable law.
(f) Other Compliance With Law. Otherwise use its best efforts to comply
with all applicable rules and regulations of the Commission.
(g) Transfer Agent and Registrar. Provide a transfer agent and
registrar (which may be the same entity) for the Conversion Shares.
Section 6. INDEMNIFICATION
(a) The Company will indemnify each Stockholder whose Conversion Shares
are included in any registration hereunder and each of its officers, directors,
and partners and each person controlling such Stockholders within the meaning of
Section 15 of the Securities Act, and each underwriter, if any, and each of its
officers, directors and partners, and each person who controls any underwriter
within the meaning of Section 15 of the Securities Act, against all expenses,
claims, losses, damages and liabilities (and actions in respect thereof
commenced or threatened), arising out of or based on any untrue statement (or
alleged untrue statement) of a material fact contained in any registration
statement or prospectus, or any amendment or supplement thereto, incident to any
such registration, or based on any omission (or alleged omission) to state
therein a material fact required to be stated therein or necessary to make the
statements therein, in light of the circumstances in which they were made, not
misleading, or any violation by the Company of any rule or regulation
promulgated under the Securities Act applicable to the Company and will
reimburse each such Stockholder, each of its officers, directors, and partners,
and each person controlling such Stockholder, each such underwriter, each of its
officers, directors, and partners and each person who controls any such
underwriter, for any legal expenses and any other expenses reasonably incurred
in connection with investigating, preparing or defending any such claim, loss,
damage, liability, or action, provided that the Company will not be liable in
any such case to the extent that any such claim, loss, damage, liability, or
expense arises out of or is based on any untrue statement or omission or alleged
untrue statement or omission, made in reliance upon and in conformity with
information furnished to the Company by such Stockholder or underwriter for use
therein. The indemnity agreement contained in this Section 6(a) shall not apply
to amounts paid in settlement of any such loss, claim, damage, liability, or
action if such settlement is effected without the consent of the Company (which
consent has not been unreasonably withheld).
(b) Each Stockholder whose Conversion Shares are included in such
registration will indemnify the Company, and each of its directors and officers,
each underwriter, if any, and each of its officers, directors, and partners, and
each person who controls the Company or such underwriter within the meaning of
Section 15 of the Securities Act, against all claims, losses, damages and
liabilities (and actions in respect thereof commenced or threatened) arising out
of or based on any untrue statement (or alleged untrue statement) of a material
fact contained in any such registration statement or prospectus, or any
amendment or supplement thereto, incident to any such registration,
6
<PAGE>
or any omission (or alleged omission) to state therein a material fact required
to be stated therein or necessary to make the statement therein not misleading,
and will reimburse the Company and such underwriters, directors, officers,
partners, or control persons for any legal expenses for any other expenses
reasonably incurred in connection with investigation or defending any such
claim, loss, damage, liability, or action, in each case to the extent that such
untrue statement (or alleged untrue statement) or omission (or alleged omission)
resulted from the Company's reliance upon information furnished by such
Stockholder. The indemnity agreement contained in this Section 6(b) shall not
apply to amounts paid in settlement of any such loss, claim, damage, liability,
or action if such settlement is effected without the consent of the each
Stockholder (which consent has not been unreasonably withheld).
(d) Each party entitled to indemnification under this Section 6 (the
"Indemnified Party") shall give notice to the party required to provide
indemnification (the "Indemnifying Party") promptly after the Indemnified Party
has actual knowledge of any claim as to which indemnity may be sought and shall
permit the Indemnifying Party to assume the defense of such claim or any
litigation resulting therefrom provided that counsel for the Indemnifying Party,
who shall conduct the defense of such claim or any litigation resulting
therefrom shall be approved by the Indemnified Party (whose approval shall not
be unreasonably withheld), and the Indemnified Party may participate in such
defense at such party's expense, and provided further that the failure of any
Indemnified Party to give notice as provided herein shall not relieve the
Indemnifying Party of its obligations under this Section 6, to the extent such
failure is not prejudicial. No Indemnifying Party in the defense of any such
claim or litigation, shall, except with the consent of each Indemnified Party,
consent to the entry of any judgment or enter into any settlement that does not
include as an unconditional term thereof the giving by the claimant or plaintiff
to such Indemnified Party of a release from all liability in respect to such
claim or litigation. Each Indemnified Party shall furnish such information
regarding itself or the claim in question as an Indemnifying Party may
reasonably request in writing as shall be reasonably required in connection with
the defense of such claim and litigation resulting therefrom.
(d) To the extent any indemnification by an indemnifying party is
prohibited or limited by law, the indemnifying party agrees to make the maximum
contribution with respect to any amounts for which it would otherwise be liable
under this Section 6 to the fullest extent permitted by law; provided, however,
that contribution by any seller of the Conversion Shares shall be limited in
amount to the net amount of proceeds received by such seller from the sale of
such Conversion Shares.
Section 7. GENERAL
(a) Defined Terms. Capitalized terms not defined herein
shall have the meanings attributed to them in the Purchase Agreement.
(b) Notices. Any notice or other communication required or
which may be given hereunder shall be in writing and shall be deemed to have
been duly given on the date delivered if delivered personally or sent by
facsimile to the persons identified below,
7
<PAGE>
one business day following deposit with a reputable overnight courier, or three
business days after deposit in the U.S. mail if mailed by certified or
registered mail, return receipt requested, addressed as follows:
If to the Company, to:
PharmaKinetics Laboratories, Inc.
302 West Fayette Street
Baltimore, MD 21201
Attention: James K. Leslie, President
Telephone: (410) 385-4500
Facsimile: (410) 385-1957
with a copy to:
Ober, Kaler, Grimes & Shriver
120 E. Baltimore Street
Baltimore, MD 21202
Attention: Melissa A. Warren, Esquire
Telephone: (410) 347-7684
Facsimile: (410) 547-0699
If either Stockholder, to:
CAI Advisors & Co.
767 Fifth Avenue, 5th Floor
New York, NY 10153
Attention: Leslie B. Daniels
Telephone: (212) 319-2525
Facsimile: (212) 319-0232
with a copy to:
Dyer Ellis & Joseph PC
600 New Hampshire Ave., N.W.
Washington, DC 20037
Attn: Michael Joseph
Telephone: (202) 944-3000
Facsimile: (202) 944-3068
Any party may change its address to which notices or other communications are to
be sent by giving written notice of any such change in the manner provided
herein for giving notice.
8
<PAGE>
(c) Assignment. The Stockholders' rights to have the Company
register the Conversion Shares pursuant to this Agreement automatically shall be
assigned to any party to whom the rights to purchase the Shares and the Warrants
have been assigned pursuant to Section 1.1 of the Purchase Agreement if: (a) the
Company is, within a reasonable time after such transfer, furnished with written
notice of (i) the name and address of such transferee and (ii) a description of
the securities transferred.
(d) Lockup Agreement. If requested by the Company and its
underwriter in connection with the registration of Conversion Shares in a firmly
underwritten public offering, each holder of Conversion Shares being registered
shall agree not to sell, transfer or otherwise dispose of any Conversion Shares
or other securities of the Company held by such holder (other than those being
registered) for a period following the effective date of the registration
statement identified by the Company and such underwriter not to exceed 60 days.
(e) Entire Agreement. This Agreement embodies the entire
agreement and understanding between the parties hereto relating to the subject
matter hereof and supersedes any prior letters of intent, agreements, and
understandings relating to the subject matter hereof.
(f) Modification or Waiver. This Agreement may be amended,
modified, or superseded at any time by a written instrument executed by the
Company and each Stockholder, and any of the terms, covenants, representations,
warranties, or conditions hereof may be waived by the party intended to be
benefited hereby. No waiver of any nature, in any one or more instances, shall
be deemed to be or construed as a further or continued waiver of any condition
or any breach of any other term, representation, or warranty in this Agreement.
(g) Counterparts. Separate copies of this Agreement may be
signed by the parties hereto, with the same effect as though all of the parties
had signed one copy of this Agreement.
(h) Severability. If any provision of this Agreement shall be
held invalid under any applicable law, such invalidity shall not affect any
other provision of this Agreement that can be given effect without the invalid
provision and, to this end, the provisions hereof are severable.
(i) Governing Law. This Agreement shall be governed by and
construed in accordance with the laws of the state of Maryland.
9
<PAGE>
IN WITNESS WHEREOF, the undersigned parties have executed this
Agreement as of the date first above written.
PHARMAKINETICS LABORATORIES, INC.
By:
James K. Leslie
President
CAI ADVISORS & CO.
By:
Leslie B. Daniels
Partner
ASTERo CEPHAC S.A.
By:
John J. Thebault
Chief Executive and President
10
